<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":8.117761,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVXWk9WA1dcABxeRwlZ","queueTime":0,"ttGuid":"f5b985bc1a56a9c7"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full">
<meta property="description" name="description" content="PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA r...">
<meta property="og:title" name="title" content="Frontiers | Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction">
<meta property="og:description" name="description" content="PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA r...">
<meta name="keywords" content="breast cancer,breast cancer predisposition genes,PALB2,BRCA2,VUS,Functional analyses,BRCA2-PALB2 interacting domains">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="8">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2018.00480">
<meta name="citation_firstpage" content="410473">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction">
<meta name="citation_keywords" content="breast cancer; breast cancer predisposition genes; PALB2; BRCA2; VUS; Functional analyses; BRCA2-PALB2 interacting domains">
<meta name="citation_abstract" content="PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA repair by homologous recombination. Germline pathogenic variants in BRCA1, BRCA2 and PALB2 DNA repair genes are associated with high risk of developing breast cancer. Mutation screening in these breast cancer predisposition genes is routinely performed and allows the identification of individuals who carry pathogenic variants and are at risk of developing the disease. However, variants of uncertain significance (VUSs) are often detected and establishing their pathogenicity and clinical relevance remains a central challenge for the risk assessment of the carriers and the clinical decision-making process. Many of these VUSs are missense variants leading to single amino acid substitutions, whose impact on protein function is uncertain. Typically, VUSs are rare and due to the limited genetic, clinical, and pathological data the multifactorial approaches used for classification cannot be applied. Thus, these variants can only be characterized through functional analyses comparing their effect with that of normal and mutant gene products used as positive and negative controls.Performing mutation testing in breast cancer probands, we identify The two missense variants BRCA2:c.91T>G (p.Trp31Gly) and PALB2:c.3262C>T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. These variants were located in the BRCA2-PALB2 interacting domains, were predicted to be deleterious by in silico analyses, and were very rare and clinically not classified. Therefore, we initiate to study their functional effect by exploiting a green fluorescent protein (GFP)-reassembly in vitro assay specifically designed to test the BRCA2-PALB2 interaction. This functional assay proved to be easy to develop, robust and reliable. It also allows testing variants located in different genes. Results from these functional analyses showed that the BRCA2:p.Trp31Gly and the PALB2:p.Pro1088Ser prevented the BRCA2-PALB2 binding. While caution is warranted when the interpretation of the clinical significance of rare VUSs is based on functional studies only, our data provide initial evidences in favor of the possibility that these variants are pathogenic.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2018/10/08">
<meta name="citation_publication_date" content="2018/10/25">
<meta name="citation_author" content="Caleca, Laura ">
<meta name="citation_author_institution" content="Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy">
<meta name="citation_author" content="Catucci, Irene ">
<meta name="citation_author_institution" content="Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy">
<meta name="citation_author" content="Figlioli, Gisella ">
<meta name="citation_author_institution" content="Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy">
<meta name="citation_author" content="De Cecco, Loris ">
<meta name="citation_author_institution" content="Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy">
<meta name="citation_author" content="Pesaran, Tina ">
<meta name="citation_author_institution" content="Ambry Genetics, Department of Clinical Diagnostics, United States">
<meta name="citation_author" content="Ward, Maggie ">
<meta name="citation_author_institution" content="Cancer Outreach and Risk Assessment, Via Christi Hospitals, United States">
<meta name="citation_author" content="Volorio, Sara ">
<meta name="citation_author_institution" content="IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Italy">
<meta name="citation_author" content="Falanga, Anna ">
<meta name="citation_author_institution" content="Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Italy">
<meta name="citation_author" content="Marchetti, Marina ">
<meta name="citation_author_institution" content="Cogentech Cancer Genetics Test Laboratory, Italy">
<meta name="citation_author" content="Iascone, Maria ">
<meta name="citation_author_institution" content="USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII, Italy">
<meta name="citation_author" content="Tondini, Carlo ">
<meta name="citation_author_institution" content="Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Italy">
<meta name="citation_author" content="Zambelli, Alberto ">
<meta name="citation_author_institution" content="Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Italy">
<meta name="citation_author" content="Azzollini, Jacopo ">
<meta name="citation_author_institution" content="Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy">
<meta name="citation_author" content="Manoukian, Siranoush ">
<meta name="citation_author_institution" content="Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy">
<meta name="citation_author" content="Radice, Paolo ">
<meta name="citation_author_institution" content="Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy">
<meta name="citation_author" content="Peterlongo, Paolo ">
<meta name="citation_author_institution" content="Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy">
<meta name="dc.identifier" content="doi:10.3389/fonc.2018.00480">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction","author":[{"@type":"Person","name":"Laura Caleca","affiliation":["Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"]},{"@type":"Person","name":"Irene Catucci","affiliation":["Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy"]},{"@type":"Person","name":"Gisella Figlioli","affiliation":["Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy"]},{"@type":"Person","name":"Loris De Cecco","affiliation":["Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"]},{"@type":"Person","name":"Tina Pesaran","affiliation":["Ambry Genetics, Department of Clinical Diagnostics, United States"]},{"@type":"Person","name":"Maggie Ward","affiliation":["Cancer Outreach and Risk Assessment, Via Christi Hospitals, United States"]},{"@type":"Person","name":"Sara Volorio","affiliation":["IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Italy","Cogentech Cancer Genetics Test Laboratory, Italy"]},{"@type":"Person","name":"Anna Falanga","affiliation":["Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Italy"]},{"@type":"Person","name":"Marina Marchetti","affiliation":["Cogentech Cancer Genetics Test Laboratory, Italy"]},{"@type":"Person","name":"Maria Iascone","affiliation":["USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII, Italy"]},{"@type":"Person","name":"Carlo Tondini","affiliation":["Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Italy"]},{"@type":"Person","name":"Alberto Zambelli","affiliation":["Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Italy"]},{"@type":"Person","name":"Jacopo Azzollini","affiliation":["Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"]},{"@type":"Person","name":"Siranoush Manoukian","affiliation":["Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"]},{"@type":"Person","name":"Paolo Radice","affiliation":["Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy"]},{"@type":"Person","name":"Paolo Peterlongo","affiliation":["Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy"]}],"datePublished":"2018-10-25","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2018","isPartOf":{"@type":"PublicationVolume","volumeNumber":"8","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2018.00480"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 25 October 2018</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Molecular and Cellular Oncology</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 8 - 2018 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2018.00480">https://doi.org/10.3389/fonc.2018.00480</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Accomplishments, Collaborative Projects and Future Initiatives in Breast Cancer Genetic Predisposition</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 13 articles" href="https://www.frontiersin.org/research-topics/7106/accomplishments-collaborative-projects-and-future-initiatives-in-breast-cancer-genetic-predisposition/magazine" target="_self" data-event="customLink-linkType-a_viewAll13Articles"><span>View all 13 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/612988" class="user-id-612988"><img class="pr5" src="https://loop.frontiersin.org/images/profile/612988/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Laura Caleca">Laura Caleca</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/565028" class="user-id-565028"><img class="pr5" src="https://loop.frontiersin.org/images/profile/565028/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Irene Catucci">Irene Catucci</a><sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Gisella Figlioli" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Gisella Figlioli<sup>2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Loris De Cecco" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Loris De Cecco<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/581161" class="user-id-581161"><img class="pr5" src="https://loop.frontiersin.org/images/profile/581161/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Tina Pesaran">Tina Pesaran</a><sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/581114" class="user-id-581114"><img class="pr5" src="https://loop.frontiersin.org/images/profile/581114/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Maggie Ward">Maggie Ward</a><sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sara Volorio," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sara Volorio<sup>6,7</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/441249" class="user-id-441249"><img class="pr5" src="https://loop.frontiersin.org/images/profile/441249/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Anna Falanga">Anna Falanga</a><sup>8</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Marina Marchetti" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Marina Marchetti<sup>7</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Maria Iascone" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Maria Iascone<sup>9</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Carlo Tondini" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Carlo Tondini<sup>10</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Alberto Zambelli" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Alberto Zambelli<sup>10</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jacopo Azzollini" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jacopo Azzollini<sup>11</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Siranoush Manoukian" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Siranoush Manoukian<sup>11</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/525518" class="user-id-525518"><img class="pr5" src="https://loop.frontiersin.org/images/profile/525518/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Paolo Radice">Paolo Radice</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/489555" class="user-id-489555"><img class="pr5" src="https://loop.frontiersin.org/images/profile/489555/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Paolo Peterlongo*">Paolo Peterlongo</a><sup>2</sup><sup>*</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</li>
<li><span><sup>2</sup></span>Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Milan, Italy</li>
<li><span><sup>3</sup></span>Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</li>
<li><span><sup>4</sup></span>Ambry Genetics, Department of Clinical Diagnostics, Aliso Viejo, CA, United States</li>
<li><span><sup>5</sup></span>Cancer Outreach and Risk Assessment, Via Christi Hospitals, Wichita, KS, United States</li>
<li><span><sup>6</sup></span>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy</li>
<li><span><sup>7</sup></span>Cogentech Cancer Genetics Test Laboratory, Milan, Italy</li>
<li><span><sup>8</sup></span>Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy</li>
<li><span><sup>9</sup></span>USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy</li>
<li><span><sup>10</sup></span>Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy</li>
<li><span><sup>11</sup></span>Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy</li>
</ul>
<p>PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA repair by homologous recombination. Germline pathogenic variants in <i>BRCA1, BRCA2</i> and <i>PALB2</i> DNA repair genes are associated with high risk of developing breast cancer. Mutation screening in these breast cancer predisposition genes is routinely performed and allows the identification of individuals who carry pathogenic variants and are at risk of developing the disease. However, variants of uncertain significance (VUSs) are often detected and establishing their pathogenicity and clinical relevance remains a central challenge for the risk assessment of the carriers and the clinical decision-making process. Many of these VUSs are missense variants leading to single amino acid substitutions, whose impact on protein function is uncertain. Typically, VUSs are rare and due to the limited genetic, clinical, and pathological data the multifactorial approaches used for classification cannot be applied. Thus, these variants can only be characterized through functional analyses comparing their effect with that of normal and mutant gene products used as positive and negative controls. The two missense variants <i>BRCA2</i>:c.91T &#x0003E;G (p.Trp31Gly) and <i>PALB2</i>:c.3262C &#x0003E;T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. These variants were located in the BRCA2-PALB2 interacting domains, were predicted to be deleterious by <i>in silico</i> analyses, and were very rare and clinically not classified. Therefore, we initiate to study their functional effect by exploiting a green fluorescent protein (GFP)-reassembly <i>in vitro</i> assay specifically designed to test the BRCA2-PALB2 interaction. This functional assay proved to be easy to develop, robust and reliable. It also allows testing variants located in different genes. Results from these functional analyses showed that the <i>BRCA2</i>:p.Trp31Gly and the <i>PALB2</i>:p.Pro1088Ser prevented the BRCA2-PALB2 binding. While caution is warranted when the interpretation of the clinical significance of rare VUSs is based on functional studies only, our data provide initial evidences in favor of the possibility that these variants are pathogenic.</p>
<div class="clear"></div></div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Approximately 20% of the familial aggregation of breast cancer is related to the presence of germline pathogenic variants in the tumor suppressor high-risk genes <i>BRCA1</i> (MIM&#x00023;113705) and <i>BRCA2</i> (MIM&#x00023;600185) [reviewed in (<a href="#B1">1</a>)]. Additional germline variants in several other genes, including <i>PALB2</i> (partner and localizer of BRCA2) (MIM&#x00023;610355) have also been implicated in increased predisposition to breast cancer (<a href="#B2">2</a>, <a href="#B3">3</a>). Estimated cumulative breast cancer risk by age of 70 conferred by pathogenic variants in <i>BRCA1</i> and <i>BRCA2</i> is approximately 60 and 50%, respectively (<a href="#B4">4</a>, <a href="#B5">5</a>). Loss of function <i>PALB2</i> pathogenic variants confer a breast cancer risk of 35% by age of 70, that is comparable to that conferred by <i>BRCA2</i> pathogenic variants (<a href="#B6">6</a>). Sequencing of these genes has become a key step of the clinical management of breast cancer families as the carriers of a pathogenic variants may be offered appropriate surveillance programs or risk reducing options, whereas the non-carriers may be advised to follow the same recommendations offered to the general population (<a href="#B7">7</a>).</p>
<p class="mb15">The clinical utility and efficacy of genetic testing rely on the possibility to establish a correlation between the detected genetic variant and its protein functional effect. As an example, pathogenicity is generally inferred for variants introducing premature termination codons (PTCs), or affecting mRNA integrity and/or stability that give rise to functionally compromised proteins. However, the assessment of the clinical relevance of other variants, especially those that are rare, may not be equally straightforward. These are referred to as variants of uncertain significance (VUSs) and typically include missense variants, small in-frame deletions or insertions, exonic and intronic alterations potentially affecting the mRNA splicing, and variants in regulatory sequences (<a href="#B4">4</a>, <a href="#B8">8</a>). Many of such variants located in the <i>BRCA1, BRCA2</i>, and <i>PALB2</i> genes have been deposited as &#x0201C;unclassified&#x0201D; in publicly available databases. The current approach to clinically classify a VUS is the multifactorial likelihood prediction model in which, data from epidemiological, genetic, pathological and clinical analyses are combined in order to derive a posterior likelihood of pathogenicity. However, reaching odds ratios in favor of or against causality requires such analyses to be based on several independent observations or to be carried out in large sample series which are usually difficult to obtain if a variant is rare (<a href="#B9">9</a>, <a href="#B10">10</a>). This provides a compelling rationale to the inclusion in the multifactorial model of additional experimental evidences. As a possibility, VUSs &#x02014;especially those located in the coding regions&#x02014;can be studied using <i>in vitro</i> and functional assays that compare the effect of normal and mutant gene products.</p>
<p class="mb15">At the molecular level, PALB2 was identified as a binding partner of BRCA2 and was subsequently shown to bridge, via direct protein-protein interaction, BRCA1 and BRCA2 at sites of DNA damage (<a href="#B11">11</a>&#x02013;<a href="#B13">13</a>). Here, this complex promotes the repair by homologous recombination (HR) of the highly genotoxic DNA lesions, such as double-strand breaks (DSBs) or inter-strand crosslinks (ICLs) (<a href="#B14">14</a>, <a href="#B15">15</a>). These BRCA1-PALB2-BRCA2 interactions are mediated via the coiled-coil domains located at the N-terminus of PALB2 (amino acids 9-44) and at the C-terminus of BRCA1 (amino acids 1,393&#x02013;1,424), and by the seven-bladed &#x003B2;-propeller WD40 (tryptophan-aspartic acid rich) domain of the C-terminal end of PALB2 (amino acids 836&#x02013;1,186) binding a domain in the N-terminal end of the BRCA2 (amino acids 21&#x02013;39) (<a href="#B16">16</a>, <a href="#B17">17</a>). Functional assays based on these domain bindings were used to study patient-derived missense variants in <i>BRCA1</i> and <i>BRCA2</i> to provide evidence in favor of or against pathogenicity. Three <i>BRCA2</i> missense variants, the c.73G&#x0003E;A (p.Gly25Arg), c.91T&#x0003E;C (p.Trp31Arg), and c.93G&#x0003E;T (p.Trp31Cys) were found to disrupt the BRCA2-PALB2 interaction, causing deficiencies in BRCA2 localization to the nucleus and in HR mediated DSB repair (<a href="#B16">16</a>). Similarly, three <i>BRCA1</i> missense variants, the c.4198A&#x0003E;G (p.Met1400Val), c.4220T&#x0003E;C (p.Leu1407Pro), and c.4232T&#x0003E;C (p.Met1411Thr) abrogated or moderately impaired the BRCA1-PALB2 binding, causing reduced HR activity (<a href="#B17">17</a>, <a href="#B18">18</a>). To date, only few patient-derived missense variants in the <i>PALB2</i> gene have been investigated for pathogenicity. Among these, the <i>PALB2</i>:c.104T&#x0003E;C (p.Leu35Pro), located in the coiled-coil domain, was found to co-segregate with two breast cancer cases in a family with a strong history for the disease, and was shown to abrogate the BRCA1-PALB2 binding and to completely prevent HR and resistance to DNA damaging agents. As a result, the p.Leu35Pro was suggested to be a pathogenic variant (<a href="#B19">19</a>) and is to our knowledge the sole variant in <i>PALB2</i> to date suggested to be pathogenic. All these findings emphasize that functional assays on VUS located in the BRCA1-PALB2-BRCA2 interaction domains may provide clues on their pathogenicity and that other variants affecting such interactions may be associated with breast cancer susceptibility.</p>
<p class="mb0">In the current study, we aimed to characterize functionally the two rare missense variants, <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) and <i>BRCA2</i>:c.91T&#x0003E;G (p.Trp31Gly), that were initially identified in breast cancer families and that are located in the protein interaction domains. These two variants were tested for pathogenicity using the green fluorescent protein (GFP)-reassembly <i>in vitro</i> assay that was recently developed for the study of protein-protein interactions (<a href="#B20">20</a>, <a href="#B21">21</a>).</p>
<a id="h3" name="h3"></a><h2>Patients and Methods</h2>
<h3 class="pt0">Breast Cancer Probands and Genotyping Analysis</h3>
<p class="mb15">The two female Italian breast cancer probands included in this study were originally considered eligible for clinical genetic testing in breast cancer genes, based on criteria including age of onset for breast cancer and family history for the disease. One proband, recruited at the Genetics Unit of Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT), was tested for mutations in the coding regions of <i>BRCA1</i> and <i>BRCA2</i> by massively parallel sequencing, using TruSeq Custom Amplicon v.1.2 (Illumina), and multiplex ligation-dependent probe amplification (MLPA) resulting carrier of the <i>BRCA2</i>:p.Trp31Gly. These tests were performed at Cogentech Cancer Genetic Test Laboratory (CGT Lab). The other proband, recruited at the Unit of Medical Oncology of the Ospedale Papa Giovanni XXIII in Bergamo (HPG23), was tested for mutations in the coding regions of <i>BRCA1</i> and <i>BRCA2</i> by Sanger sequencing and MLPA at Cogentech CGT Lab. No <i>BRCA1</i> or <i>BRCA2</i> mutations were detected, and so this probands was tested at Laboratorio Genetica Medica, HPG23 by massively parallel sequencing using TruSight Cancer assay (Illumina). No pathogenic or likely pathogenic variants were found and the only deleterious variant detected was the missense <i>PALB2</i>:p.Pro1088Ser variant.</p>
<p class="mb15">Genotyping of the <i>PALB2</i>:p.Pro1088Ser was performed using a custom TaqMan assay (probes and experimental conditions are available upon request). This variant was tested in familial and consecutive breast cancer cases ascertained at HPG23, and in female blood donors used as controls recruited at the AVIS Bergamo.</p>
<p class="mb0">All individuals included in this study and herein described signed an informed consent to the use of their biological samples and clinical data for research project. This study was approved by Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Ethical Committee of the Province of Bergamo.</p>
<h3>Positive/Negative Controls for the GFP-Reassembly <i>in vitro</i> Assay</h3>
<p class="mb0">Six <i>BRCA2</i> or <i>PALB2</i> variants located in the protein interaction domain were included as positive and negative controls. The <i>PALB2</i>:c.2816T&#x0003E;G (p.Leu939Trp) variant was reported to be not associated with breast cancer risk and to not alter the protein DNA repair activity by HR (<a href="#B22">22</a>, <a href="#B23">23</a>). The <i>BRCA2</i>:c.79A&#x0003E;G (p.Ile27Val) and <i>PALB2</i>:c.3064AT&#x0003E;GC (p.Met1022Ala) missense variants were functionally tested and resulted not disrupting the BRCA2-PALB2 interaction (<a href="#B16">16</a>, <a href="#B24">24</a>). These three variants were used as positive controls. The three missense variants <i>BRCA2</i>:c.93G&#x0003E;T (p.Trp31Cys), <i>BRCA2</i>:c.91T&#x0003E;C (p.Trp31Arg) and <i>PALB2</i>:c. 3073G&#x0003E;A (p.Ala1025Arg) were reported to functionally prevent the BRCA2-PALB2 binding and were used as negative controls (<a href="#B16">16</a>, <a href="#B24">24</a>). All of these variants were patient-derived with the exception of the <i>PALB2</i>:p.Met1022Ala and <i>PALB2</i>:p.Ala1025Arg that were synthetically designed based on crystallography analyses.</p>
<h3>Plasmid Construction</h3>
<p class="mb0">The pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP expression vectors, encoding anti-parallel leucine zipper motifs (Z) fused to the N-terminal or C-terminal fragment of the GFP Protein (NfrGFP and CfrGFP, respectively) (<a href="#B20">20</a>) were kindly donated by TJ Magliery from the Ohio State University in Columbus (OH, USA). The DNA fragments encoding the N-terminal end of BRCA2 (amino acids 10&#x02013;40) and the WD40 domain of PALB2 (amino acids 836-1186) were amplified from the cDNA of the 293T cells by PCR. The purified PCR products were subcloned into pET11a-NfrGFP between <i>XhoI</i> and <i>BamHI</i> restriction sites and pMRBAD-Z-CfrGFP between <i>NcoI</i> and <i>AatII</i> restriction sites, replacing the fragments encoding Z motifs. The <i>BRCA2</i> c.79A&#x0003E;G (p.Ile27Val), c.91T&#x0003E;C (p.Trp31Arg), c.91T&#x0003E;G (p.Trp31Gly), c.93G&#x0003E;T (p.Trp31Cys) and the <i>PALB2</i> c.2816T&#x0003E;G (p.Leu939Trp), c.3073G&#x0003E;A (p.Ala1025Arg), c.3266C&#x0003E;T (p.Pro1088Ser) variants were obtained by direct mutagenesis of pET11a-NfrGFP-BRCA2 and of pMRBAD-PALB2-CfrGFP using the QuickChange XL Site-directed Mutagenesis Kit (Stratagene) according to the manufacturer&#x00027;s instruction. The <i>PALB2</i> c.3064AT&#x0003E;GC (p.Met1022Ala) was obtained by the overlap extension PCR mutagenesis method (<a href="#B25">25</a>). The presence of variants in recombinant clones was verified by DNA sequencing (Eurofins Genomics).</p>
<h3>GFP-Fragment Reassembly Screening</h3>
<p class="mb0">Compatible pairs of plasmids (pET11a-NfrGFP-BRCA2 and pMRBAD-PALB2-CfrGFP, both as wild-type and mutant forms) were co-transformed into BL21 (DE3) <i>E. coli</i> competent cells by electroporation. Single colonies were then picked and used to inoculate 2 ml of LB broth medium containing ampicillin (100 &#x003BC;g/ml) and kanamycin (35 &#x003BC;g/ml). Following overnight incubation at 37&#x000B0;C, the cultured cells were diluted 1:1,000 and 100 &#x003BC;l were plated on inducing LB agar (LBA) plates supplemented with 20 &#x003BC;M Isopropyl &#x003B2;-D-1-tiogalattopiranoside (IPTG) and 0.2% L-arabinose, to promote the expression of recombinant proteins. The plates were incubated at 30&#x000B0;C for 24 h and then 3 days at room temperature (RT). Fluorescence was observed after excitation with long-wave (365 nm) UV light in combination with the short pass (SP) emission filter using a Syngene image capture system (SYNGENE) as specified by the manufacturer.</p>
<h3>Purification of the Reassembled GFP Complexes</h3>
<p class="mb15">The pET11a-NfrGFP-BRCA2 (both wt and mutant forms) also encode a hexa histidine (H<sub>6</sub>)-tag at the N-terminus of the NfrGFP useful for rapid purification by Immobilized metal affinity chromatography (IMAC) method of the H<sub>6</sub>-tagged proteins. This method exploits the strong binding of H<sub>6</sub>-tagged protein to metal ions as nickel, allowing them to be separated from other proteins that have lower or no affinity.</p>
<p class="mb0">Co-transformed bacterial cells were recovered from inducing LBA media using a plate spreader and resuspended in two 1 ml-aliquots of 1X phosphate buffered saline (PBS). After centrifugation, each pellet was resuspended in 50 &#x003BC;l of 1xSDS loading buffer (whole cell extracts), or in 1 ml of lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 0.1% v/v Triton X-100, 100 &#x003BC;M EDTA pH8.0, 0.5 mg/ml lysozime, 20 mM Imidazole, protease inhibitors, 5 &#x003BC;g/ml DNase and RNase) for IMAC purification using the nickel nitrilotriacetic (Ni-NTA) agarose resin (QIAGEN), following the manufacturer&#x00027;s instructions. The purified protein complexes were subjected to 13% SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody (&#x00023;600-101-215; Rockland). Whole cell extracts were similarly resolved and visualized, to detect expression levels of the all NfrGFP-BRCA2 and CfrGFP-PALB2 fusion peptides.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Identification of the <i>BRCA2</i>:c.91t&#x0003E;G (p.Trp31Gly) and the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) Variants</h3>
<p class="mb0">Part of our research activity stems from the collaboration with several Breast Cancer Units in which clinical genetic testing is routinely performed. One of our major interest is to functionally study and characterize VUSs in breast cancer genes. In this study, we report the identification and describe the initial functional analyses of the <i>BRCA2</i>:p.Trp31Gly and the <i>PALB2</i>:p.Pro1088Ser variants. The <i>BRCA2</i>:p.Trp31Gly and the <i>PALB2</i>:p.Pro1088Ser variants were originally identified in two different Italian breast cancer probands born in Milano and Bergamo, respectively and are located in the BRCA2-PALB2 interacting domains. Both these probands developed breast cancer at a young age and reported a close relative affected with early onset breast cancer (&#x02264; 40 years). Unfortunately, we were not able to ascertain other family members to be genotyped in order to attempt co-segregation analyses (Figure <a href="#F1">1</a>). None of these two variants were reported in public databases such as GnomAD and 1000 genomes. However, the <i>BRCA2</i>: &#x0003C; <i>underline</i> &#x0003E;p.Trp31Gly was annotated in ClinVar (<a href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</a>) in a single individual submitted by Ambry Genetics and classified as a VUS. On the contrary, the <i>PALB2</i>:p.Pro1088Ser was not found in any of the clinical databases we searched. However, during the last annual meeting of the <i>PALB2</i> Interest Group (PIG; <a href="http://www.palb2.org/">http://www.palb2.org/</a>) colleagues from Ambry Genetics reported the finding of an additional carrier of the <i>PALB2</i>:p.Pro1088Ser variant. To our knowledge, to date, this is only the second proband found to carry this variant. For this reason, we report here his clinical phenotype and family cancer history. This proband was a male affected with colorectal polyps, type unknown, and from a family with cases of melanoma and pancreatic cancer but not breast cancers (Figure <a href="#F2">2</a>). Unfortunately, also in this case, no other samples were available for genotyping. We previously reported two different founder mutations, the <i>PALB2</i>:c.1027C&#x0003E;T (p.Gln343*) and the <i>BRCA2</i>:c.190T&#x0003E;C (p.Cys64Arg), originally identified in the Bergamo province where they have a carrier frequency approximately 10-fold higher than that of the Italian population (<a href="#B21">21</a>, <a href="#B26">26</a>, <a href="#B27">27</a>). Hence, we genotyped the <i>PALB2</i>:p.Pro1088Ser in 126 familial and 477 consecutive breast cancer cases, and 1,074 controls all born in the province of Bergamo but no additional carriers were found.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1</strong>. The <i>BRCA2</i>:c.91T&#x0003E;G (p.Trp31Gly) and the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) variants, and pedigrees of the two mutation carriers. <strong>(A)</strong> Electropherograms showing the <i>BRCA2</i> and <i>PALB2</i> sequence of the individuals carrying the two variants, and normal controls. <strong>(B)</strong> Family pedigrees 1 and 2 of the two Italians probands carrying the <i>BRCA2</i>:c.91T&#x0003E;G (p.Trp31Gly;) and the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) variants, respectively. Probands are indicated by arrow. Cancer type, age at diagnosis and age of death are reported when known. Age of healthy individuals, if known, was annotated at date of genetic counseling. Events occurred after genetic counseling, if known, are annotated. Additional relatives carrying the variants are indicated by &#43;/&#x02013;. Cancer type is reported as follows: Bl, bladder cancer; Br, breast cancer; CR, colorectal cancer; Le, leukemia; Lu, lung cancer.</p></div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2</strong>. Family pedigree of the additional proband carrying the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) variant. The proband had large multi gene panel test (67 genes) due to a family history of cancer. The analysis was performed at the Ambry Genetics using Next Generation Sequencing and Array CGA (<a style="color:grey;" href="https://www.ambrygen.com/clinician/genetic-testing/28/oncology/cancernext-expanded">https://www.ambrygen.com/clinician/genetic-testing/28/oncology/cancernext-expanded</a>). Proband is indicated by arrow. Cancer type, age at diagnosis and age of death are reported when known. Age of healthy individuals, if known, was annotated at date of genetic counseling. Events occurred after genetic counseling, if known, are annotated. Cancer type is reported as follows: BC, basal cells cancer; Bl, bladder cancer; Me, melanoma; Pa, pancreatic cancer; Pr, prostate cancer; Un, unknown.</p></div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>The <i>BRCA2</i>:c.91T&#x0003E;G (p.Trp31Gly) and the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) Variants Prevent the BRCA2-PALB2 Binding</h3>
<p class="mb0">The <i>BRCA2</i>:c.91T&#x0003E;G and the <i>PALB2</i>:c.3262C&#x0003E;T variants were located within the protein domains mediating the BRCA2-PALB2 interaction (Figure <a href="#F3">3A</a>). To evaluate the effect of these variants on the BRCA2-PALB2 interaction, we exploited a bimolecular fluorescence complementation-based assay, the GFP-reassembly <i>in vitro</i> assay. In this assay, the GFP is dissected into two fragments, the N-terminal, NfrGFP and the C-terminal, CfrGFP which are fused to the N-terminal end of BRCA2 (amino acids 10-40) and the WD40 domain of PALB2 (amino acids 836-1186), respectively. These two plasmids are co-expressed in BL21 (DE3) <i>E. coli</i> cells and only if BRCA2-PALB2 interaction occurs, the GFP reassemble emitting cellular fluorescence after ultraviolet (UV) irradiation.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3</strong>. Detection of the BRCA2-PALB2 interaction. <strong>(A)</strong> Schematic representation of the specific domains mediating the BRCA2-PALB2 binding and of the location of variants analyzed in the present study. <strong>(B)</strong> GFP-reassembly <i>in vitro</i> assay. Fluorescence was recovered, under long-wave UV light (365 nm), after 24 h of growth at 30&#x000B0;C followed by 3 days of incubation at room temperature. The variants PALB2 L939W or M1022A and BRCA2 I27V were included as positive controls. The variants PALB2 A1025R and BRCA2 W31C or W31R were included as negative controls. <strong>(C)</strong> IMAC purification. The BRCA2-PALB2 reassembled complexes were purified from the co-transformed <i>E. coli</i> BL21 (DE3) cells, subjected to SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody. <strong>(D)</strong> Analysis of expression of BRCA2-NfrGFP and PALB2-CfrGFP normal and mutant forms. Whole cell extracts from the co-transformed <i>E. coli</i> BL21 (DE3) cells were subjected to SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody. Images of <strong>(C, D)</strong> were selected from original autoradiographic films shown in Supplementary Figure <a style="color:grey;" href="#SM1">1</a>.</p></div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Bright GFP fluorescence was observed in bacterial cells co-expressing NfrGFP fused with normal BRCA2 and CfrGFP fused with either normal PALB2, the clinically neutral variant <i>PALB2</i>:p.Leu939Trp or <i>PALB2</i>:p.Met1022Ala (positive controls). Similar results were observed in bacterial cells co-expressing CfrGFP fused with normal PALB2 and NfrGFP fused with <i>BRCA2</i>:p.Ile27Val (positive control). On the contrary, no fluorescence was observed in bacterial cells co-expressing NfrGFP fused with normal BRCA2 and CfrGFP fused with either <i>PALB2</i>:p.Pro1088Ser, or <i>PALB2</i>:p.Ala1025Arg (negative control). Similar results were observed in bacterial cells co-expressing CfrGFP fused with normal PALB2 and NfrGFP fused with either <i>BRCA2</i>:p.Trp31Gly, or the negative controls <i>BRCA2</i>:p.Trp31Cys, or <i>BRCA2</i>:p.Trp31Arg (Figure <a href="#F3">3B</a>).</p>
<p class="mb0">To confirm that GFP-reassembly was effectively due to the BRCA2-PALB2 interaction, the IMAC purified reassembled complexes were analyzed by Western blotting using a polyclonal anti-GFP antibody. Two bands corresponding to the components of the GFP reassembled complexes were detected in lysates of the bacterial cells that resulted fluorescent in the GFP-reassembly screening. On the contrary, no or low intensity bands corresponding to the PALB2-CfrGFP fused domains were observed in lysates from bacterial cells for whom no fluorescence was detected (Figure <a href="#F3">3C</a>). In general, any mutations can cause the decrease or the complete loss of expression of the encoded GFP fused peptides. Thus, we wanted to confirm that the lack or the low intensity of the PALB2-CfrGFP bands was not due to loss of expression. To this aim, the whole cell extracts were analyzed by Western blotting using a polyclonal anti-GFP antibody as previously described. In this experiment, we showed that normal and mutated fusion peptides were expressed to a similar extent indicating that the loss of fluorescence observed in the GFP-reassembly <i>in vitro</i> assay, was attributable to the lack of binding between the proteins and not to poor expression of the mutants (Figure <a href="#F3">3D</a>). All these results provided experimental evidence that both the <i>BRCA2</i>:p.Trp31Gly and the <i>PALB2</i>:p.Pro1088Ser variants abrogate the BRCA2-PALB2 binding.</p>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">In clinical settings, VUSs in breast cancer genes represent a serious issue in the process of disease risk assessment in carriers. Typically, results from different sources such as epidemiological, genetic, and clinical analyses are combined together in order to derive a posterior likelihood of pathogenicity used to classify a VUS. While this multifactorial approach is successful to classify common VUSs, variants that are rare or unique can only be studied through functional analyses.</p>
<p class="mb15">In the present study, we investigated the pathogenicity of the two <i>BRCA2</i>:p.Trp31Gly and <i>PALB2</i>:p.Pro1088Ser variants performing functional analyses. The <i>BRCA2</i>:p.Trp31Gly was previously reported in a single proband and annotated as VUS. To our knowledge, the <i>PALB2</i>:p.Pro1088Ser was never detected before. Both variants are located in the interaction domains of BRCA2 and PALB2. Large part of the BRCA2 functions in the repair of the DNA double strand breaks and inter-strand crosslinks by HR depends from its interaction with PALB2. Thus, we developed a GFP-reassembly assay based on the testing of this interaction speculating that this binding assay would be a predictor of the effect of the variants on the BRCA2 integrity.</p>
<p class="mb15">In the GFP-reassembly assay, we used six different <i>BRCA2</i> and <i>PALB2</i> missense variants as controls. Two patient-derived <i>BRCA2</i> variants, the p.Trp31Arg and p.Trp31Cys, and one synthetic <i>PALB2</i> variant, the p.Ala1025Arg, were known to prevent the BRCA2-PALB2 interaction. The patient derived <i>BRCA2</i>:p.Ile27Val and <i>PALB2</i>:Leu939Trp, and the synthetic <i>PALB2</i>:p.Met1022Ala were expected to not alter the binding of these proteins. For all of these variants, the results were concordant with their expected effect on the BRCA2-PALB2 binding.</p>
<p class="mb15">The GFP-reassembly assay results indicated that both the <i>BRCA2</i>:p.Trp31Gly and <i>PALB2</i>:p.Pro1088Ser prevented the BRCA2-PALB2 interaction suggesting that in physiological conditions these alleles encode proteins that might be unable to interact with PALB2 and BRCA2, respectively. To our knowledge, the <i>PALB2</i>:p.Pro1088Ser is the first missense variant in the gene that was functionally shown to abrogate the binding with BRCA2. As the correct formation of the BRCA1-PALB2-BRCA2 complex is necessary for DNA repair by HR, our results provide evidences in favor of the hypothesis that the <i>BRCA2</i>:p.Trp31Gly and <i>PALB2</i>:p.Pro1088Ser are pathogenic variants. While this assumption is at present most likely&#x02014;in example vs. the possibility that the variants are neutral&#x02014;other aspects need to be considered for a clearer picture of the effect of these variants on breast cancer risk. Firstly, Foo and colleagues showed that both the <i>PALB2</i>:p.Leu35Pro and p.Tyr28Cys caused the loss of the interaction with BRCA1; however, only the p.Leu35Pro completely abrogated the HR activity and the p.Tyr28Cys caused a loss of approximately 65% of the HR activity (<a href="#B19">19</a>). Hence, <i>PALB2</i> missense variants causing the loss of the binding with BRCA1 might confer different risk magnitude for breast cancer. To be conservative, we cannot exclude that this might be true as well for the PALB2 variants abrogating the binding with BRCA2. As a second point, caution should be taken when inferring on the nature of a missense variant on the bases of functional studies only. Park and colleagues reported that the <i>PALB2</i>:p.Leu939Trp variant might be pathogenic based on the fact that it resulted in altered BRCA2-PALB2 binding, decreased HR capacity, and increased sensitivity to ionizing radiation (<a href="#B28">28</a>). However, we provided strong evidences deriving from additional functional studies and very large case-control studies that the <i>PALB2</i>:p.Leu939Trp is a neutral variant (<a href="#B23">23</a>). As a final consideration, it should be noted that of the many missense variants that were functionally proved to prevent the BRCA1-PALB2-BRCA2 complex formation (<a href="#B16">16</a>, <a href="#B19">19</a>, <a href="#B24">24</a>), all, with the only exception of the <i>PALB2</i>:p.Leu939Trp that is consider benign or likely benign, are annotated or should be treated clinically as VUS.</p>
<p class="mb0">In conclusion, we report here results from functional studies indicating that the <i>BRCA2</i>:c.91T&#x0003E;G (p.Trp31Gly) and the <i>PALB2</i>:c.3262C&#x0003E;T (p.Pro1088Ser) missense variants abrogate the BRCA2-PALB2 protein binding. These data provide initial evidences corroborating the hypothesis that these variants are pathogenic. Importantly, novel data are warranted to progress in the clinical classification of these variants. The search for additional variant carriers and collection of their family members is crucial to provide genetic or pathological data; however, as the variants in study are very rare, we expect that not many variant carriers will be found in the near future. On the contrary, additional functional studies (i.e. testing specific protein functions in eukaryotic cells) could be immediately performed. While caution is warranted when clinical classification of a VUS is based on <i>in vitro</i> assays only, these results will provide additional evidences to better clarify the functional effect of the variants in study.</p>
<a id="h6" name="h6"></a><h2>Author Contributions</h2>
<p class="mb0">PP and PR designed and supervised the study. TP, MW, SV, AF, MM, MI, CT, AZ, JA, and SM provided samples and data. LC, IC, and LD performed experiments. LC, IC, GF, PP, and PR analyzed data. LC, IC, PP, and PR wrote the manuscript. All authors contributing to, critically revised and approved the manuscript.</p>
<a id="h7" name="h7"></a><h2>Funding</h2>
<p class="mb0">This work was partially supported by the following entities. Ministero della Salute, Italy Ricerca Finalizzata&#x02013;Bando 2010 to PP; AIRC (Associazione Italiana per la Ricerca sul Cancro) to PP (IG 16732), PR (IG 15547) and AF (5 &#x000D7; 1,000 n. 12237); Fondazione Umberto Veronesi (FUV-Post-doctoral Fellowships&#x02212;2016) to IC; the Italian citizens who allocated the 5 &#x000D7; 1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale dei Tumori, according to the Italian laws, to SM.</p>
<a id="h8" name="h8"></a><h2>Conflict of Interest Statement</h2>
<p class="mb15">TP is a full time paid employee of Ambry Genetics.</p>
<p class="mb0">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h9" name="h9"></a><h2>Acknowledgments</h2>
<p class="mb0">We are particularly grateful to individuals participating in this study and their families. We also thank the Real Time PCR and the DNA Sequencing Service of Cogentech, Milan, Dr. Thomas J. Magliery from the Ohio State University in Columbus (OH, USA) for kindly providing the pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP plasmids necessary for the GFP-reassembly assay, Dr. Maria Teresa Radice of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, for technical assistance with plasmid construction and Drs. Cristina Zanzottera and Roberta Villa of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.</p>
<a id="h10" name="h10"></a><h2>Supplementary Material</h2>
<p class="mb0">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2018.00480/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2018.00480/full#supplementary-material</a></p>
<a id="h11" name="h11"></a><h2>References</h2>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B1" id="B1"></a> 1. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. <i>Mol Oncol.</i> (2010) 4:174&#x02013;91. doi: 10.1016/j.molonc.2010.04.011</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20542480" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.molonc.2010.04.011" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N.+Mavaddat&#x00026;author=AC.+Antoniou&#x00026;author=DF.+Easton&#x00026;author=M.+Garcia-Closas+&#x00026;publication_year=2010&#x00026;title=Genetic+susceptibility+to+breast+cancer&#x00026;journal=Mol+Oncol.&#x00026;volume=4&#x00026;pages=174-91" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B2" id="B2"></a> 2. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. <i>N Engl J Med.</i> (2015) 372:2243&#x02013;57. doi: 10.1056/NEJMsr1501341</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26014596" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMsr1501341" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DF.+Easton&#x00026;author=PD.+Pharoah&#x00026;author=AC.+Antoniou&#x00026;author=M.+Tischkowitz&#x00026;author=SV.+Tavtigian&#x00026;author=KL.+Nathanson+&#x00026;publication_year=2015&#x00026;title=Gene-panel+sequencing+and+the+prediction+of+breast-cancer+risk&#x00026;journal=N+Engl+J+Med.&#x00026;volume=372&#x00026;pages=2243-57" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B3" id="B3"></a> 3. Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. <i>JAMA Oncol.</i> (2017) 3:1190&#x02013;6. doi: 10.1001/jamaoncol.2017.0424</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28418444" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jamaoncol.2017.0424" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FJ.+Couch&#x00026;author=H.+Shimelis&#x00026;author=C.+Hu&#x00026;author=SN.+Hart&#x00026;author=EC.+Polley&#x00026;author=J.+Na+&#x00026;publication_year=2017&#x00026;title=Associations+between+cancer+predisposition+testing+panel+genes+and+breast+cancer&#x00026;journal=JAMA+Oncol.&#x00026;volume=3&#x00026;pages=1190-6" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B4" id="B4"></a> 4. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. <i>Science</i> (2014) 343:1466. doi: 10.1126/science.1251827</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24675953" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.1251827" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FJ Nathanson KL.+Couch&#x00026;author=K.+Offit+&#x00026;publication_year=2014&#x00026;title=Two+decades+after+BRCA%3A+setting+paradigms+in+personalized+cancer+care+and+prevention&#x00026;journal=Science&#x00026;volume=343&#x00026;pages=1466" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B5" id="B5"></a> 5. Foulkes WD. BRCA1 and BRCA2&#x02014;Update and implications on the genetics of breast cancer: a clinical perspective. <i>Clin Genet.</i> (2014) 85:1&#x02013;4. doi: 10.1111/cge.12291</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24116874" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12291" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=WD.+Foulkes+&#x00026;publication_year=2014&#x00026;title=BRCA1+and+BRCA2&#x02014;Update+and+implications+on+the+genetics+of+breast+cancer%3A+a+clinical+perspective&#x00026;journal=Clin+Genet.&#x00026;volume=85&#x00026;pages=1-4" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B6" id="B6"></a> 6. Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. <i>N Engl J Med.</i> (2014) 371:1651&#x02013;2. doi: 10.1056/NEJMc1410673</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://doi.org/10.1056/NEJMc1410673" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AC.+Antoniou&#x00026;author=WD.+Foulkes&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2014&#x00026;title=Breast-cancer+risk+in+families+with+mutations+in+PALB2&#x00026;journal=N+Engl+J+Med.&#x00026;volume=371&#x00026;pages=1651-2" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B7" id="B7"></a> 7. Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. <i>Genet Med.</i> (2018). doi: 10.1038/gim.2018.44</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="https://doi.org/10.1038/gim.2018.44" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Girardi&#x00026;author=DR.+Barnes&#x00026;author=D.+Barrowdale&#x00026;author=D.+Frost&#x00026;author=AF.+Brady&#x00026;author=C.+Miller+&#x00026;publication_year=2018&#x00026;title=Risks+of+breast+or+ovarian+cancer+in+BRCA1+or+BRCA2+predictive+test+negatives%3A+findings+from+the+EMBRACE+study&#x00026;journal=Genet+Med." target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B8" id="B8"></a> 8. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. <i>Ann Oncol.</i> (2011) 22(Suppl 1):i18&#x02013;23. doi: 10.1093/annonc/mdq661</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21285146" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdq661" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=P.+Radice&#x00026;author=Summa S.+De&#x00026;author=L.+Caleca&#x00026;author=S.+Tommasi+&#x00026;publication_year=2011&#x00026;title=Unclassified+variants+in+BRCA+genes%3A+guidelines+for+interpretation&#x00026;journal=Ann+Oncol.&#x00026;volume=22&#x00026;pages=i18-23" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.1em;" class="ReferencesCopy1"><a name="B9" id="B9"></a> 9. Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. <i>Curr Opin Genet Dev.</i> (2010) 20:315&#x02013;23. doi: 10.1016/j.gde.2010.03.009</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20456937" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.gde.2010.03.009" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AB.+Spurdle+&#x00026;publication_year=2010&#x00026;title=Clinical+relevance+of+rare+germline+sequence+variants+in+cancer+genes%3A+evolution+and+application+of+classification+models&#x00026;journal=Curr+Opin+Genet+Dev.&#x00026;volume=20&#x00026;pages=315-23" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B10" id="B10"></a> 10. Lindor NM, Guidugli L, Wang X, Vall&#x000E9;e MP, Monteiro AN, Tavtigian S, et al. A review of a multifactorial probability based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). <i>Hum Mutat.</i> (2012) 33:8&#x02013;21. doi: 10.1002/humu.21627</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21990134" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.21627" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NM.+Lindor&#x00026;author=L.+Guidugli&#x00026;author=X.+Wang&#x00026;author=MP.+Vall&#x000E9;e&#x00026;author=AN.+Monteiro&#x00026;author=S.+Tavtigian+&#x00026;publication_year=2012&#x00026;title=A+review+of+a+multifactorial+probability+based+model+for+classification+of+BRCA1+and+BRCA2+variants+of+uncertain+significance+(VUS)&#x00026;journal=Hum+Mutat.&#x00026;volume=33&#x00026;pages=8-21" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B11" id="B11"></a> 11. Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY. Exploring the roles of PALB2 at the crossroads of DNA repair and cancer. <i>Biochem J.</i> (2014) 460:331&#x02013;42. doi: 10.1042/BJ20140208</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24870022" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1042/BJ20140208" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+Pauty&#x00026;author=A.+Rodrigue&#x00026;author=A.+Couturier&#x00026;author=R.+Buisson&#x00026;author=JY.+Masson+&#x00026;publication_year=2014&#x00026;title=Exploring+the+roles+of+PALB2+at+the+crossroads+of+DNA+repair+and+cancer&#x00026;journal=Biochem+J.&#x00026;volume=460&#x00026;pages=331-42" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B12" id="B12"></a> 12. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. <i>Mol Cancer Res.</i> (2009) 7:1110&#x02013;8. doi: 10.1158/1541-7786.MCR-09-0123</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19584259" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1541-7786.MCR-09-0123" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Zhang&#x00026;author=Q.+Fan&#x00026;author=K.+Ren&#x00026;author=PR.+Andreassen+&#x00026;publication_year=2009&#x00026;title=PALB2+functionally+connects+the+breast+cancer+susceptibility+proteins+BRCA1+and+BRCA2&#x00026;journal=Mol+Cancer+Res.&#x00026;volume=7&#x00026;pages=1110-8" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B13" id="B13"></a> 13. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. <i>Curr Biol.</i> (2009) 19:524&#x02013;9. doi: 10.1016/j.cub.2009.02.018</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19268590" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cub.2009.02.018" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Zhang&#x00026;author=J.+Ma&#x00026;author=J.+Wu&#x00026;author=L.+Ye&#x00026;author=H.+Cai&#x00026;author=B.+Xia+&#x00026;publication_year=2009&#x00026;title=PALB2+links+BRCA1+and+BRCA2+in+the+DNA-damage+response&#x00026;journal=Curr+Biol.&#x00026;volume=19&#x00026;pages=524-9" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B14" id="B14"></a> 14. Ceccaldi R, Sarangi P, D&#x00027;Andrea AD. The Fanconi anaemia pathway: new players and new functions. <i>Nat Rev Mol Cell Biol.</i> (2016) 17:337&#x02013;49. doi: 10.1038/nrm.2016.48</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27145721" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrm.2016.48" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Ceccaldi&#x00026;author=P.+Sarangi&#x00026;author=AD.+D&#x00027;Andrea+&#x00026;publication_year=2016&#x00026;title=The+Fanconi+anaemia+pathway%3A+new+players+and+new+functions&#x00026;journal=Nat+Rev+Mol+Cell+Biol.&#x00026;volume=17&#x00026;pages=337-49" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B15" id="B15"></a> 15. Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. <i>Cold Spring Harb Perspect Biol.</i> (2015) 7:a016600. doi: 10.1101/cshperspect.a016600</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25833843" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/cshperspect.a016600" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Prakash&#x00026;author=Y.+Zhang&#x00026;author=W.+Feng&#x00026;author=M.+Jasin+&#x00026;publication_year=2015&#x00026;title=Homologous+recombination+and+human+health%3A+the+roles+of+BRCA1,+BRCA2,+and+associated+proteins&#x00026;journal=Cold+Spring+Harb+Perspect+Biol.&#x00026;volume=7&#x00026;pages=a016600" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B16" id="B16"></a> 16. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. <i>Mol Cell</i> (2006) 22:719&#x02013;29. doi: 10.1016/j.molcel.2006.05.022</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16793542" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.molcel.2006.05.022" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B.+Xia&#x00026;author=Q.+Sheng&#x00026;author=K.+Nakanishi&#x00026;author=A.+Ohashi&#x00026;author=J.+Wu&#x00026;author=N.+Christ+&#x00026;publication_year=2006&#x00026;title=Control+of+BRCA2+cellular+and+clinical+functions+by+a+nuclear+partner,+PALB2&#x00026;journal=Mol+Cell&#x00026;volume=22&#x00026;pages=719-29" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B17" id="B17"></a> 17. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. <i>Proc Natl Acad Sci USA.</i> (2009) 106:7155&#x02013;60. doi: 10.1073/pnas.0811159106</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19369211" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1073/pnas.0811159106" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SM.+Sy&#x00026;author=MS.+Huen&#x00026;author=J.+Chen+&#x00026;publication_year=2009&#x00026;title=PALB2+is+an+integral+component+of+the+BRCA+complex+required+for+homologous+recombination+repair&#x00026;journal=Proc+Natl+Acad+Sci+USA.&#x00026;volume=106&#x00026;pages=7155-60" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B18" id="B18"></a> 18. Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. <i>Elife</i> (2017) 6:e21350. doi: 10.7554/eLife.21350</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28398198" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.7554/eLife.21350" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RW.+Anantha&#x00026;author=S.+Simhadri&#x00026;author=TK.+Foo&#x00026;author=S.+Miao&#x00026;author=J.+Liu&#x00026;author=Z.+Shen+&#x00026;publication_year=2017&#x00026;title=Functional+and+mutational+landscapes+of+BRCA1+for+homology-directed+repair+and+therapy+resistance&#x00026;journal=Elife&#x00026;volume=6&#x00026;pages=e21350" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B19" id="B19"></a> 19. Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, et al. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. <i>Oncogene</i> (2017) 36:4161&#x02013;70. doi: 10.1038/onc.2017.46</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28319063" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/onc.2017.46" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TK.+Foo&#x00026;author=M.+Tischkowitz&#x00026;author=S.+Simhadri&#x00026;author=T.+Boshari&#x00026;author=N.+Zayed&#x00026;author=KA.+Burke+&#x00026;publication_year=2017&#x00026;title=Compromised+BRCA1-PALB2+interaction+is+associated+with+breast+cancer+risk&#x00026;journal=Oncogene&#x00026;volume=36&#x00026;pages=4161-70" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B20" id="B20"></a> 20. Sarkar M, Magliery TJ. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients. <i>Mol Biosyst.</i> (2008) 4:599&#x02013;605. doi: 10.1039/b802481b</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18493658" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1039/b802481b" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Sarkar&#x00026;author=TJ.+Magliery+&#x00026;publication_year=2008&#x00026;title=Re-engineering+a+split-GFP+reassembly+screen+to+examine+RING-domain+interactions+between+BARD1+and+BRCA1+mutants+observed+in+cancer+patients&#x00026;journal=Mol+Biosyst.&#x00026;volume=4&#x00026;pages=599-605" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B21" id="B21"></a> 21. Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, et al. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. <i>PLoS ONE</i> (2014) 9:e86924. doi: 10.1371/journal.pone.0086924</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24516540" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0086924" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Caleca&#x00026;author=AL.+Putignano&#x00026;author=M.+Colombo&#x00026;author=C.+Congregati&#x00026;author=M.+Sarkar&#x00026;author=TJ.+Magliery+&#x00026;publication_year=2014&#x00026;title=Characterization+of+an+Italian+founder+mutation+in+the+RING-finger+domain+of+BRCA1&#x00026;journal=PLoS+ONE&#x00026;volume=9&#x00026;pages=e86924" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B22" id="B22"></a> 22. Southey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. <i>Hered Cancer Clin Pract.</i> (2016) 14:9. doi: 10.1186/s13053-016-0049-2</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27099641" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13053-016-0049-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MC.+Southey&#x00026;author=I.+Winship&#x00026;author=T.+Nguyen-Dumont+&#x00026;publication_year=2016&#x00026;title=PALB2%3A+research+reaching+to+clinical+outcomes+for+women+with+breast+cancer&#x00026;journal=Hered+Cancer+Clin+Pract.&#x00026;volume=14&#x00026;pages=9" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B23" id="B23"></a> 23. Catucci I, Radice P, Milne RL, Couch FJ, Southey MC, Peterlongo P. The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk. <i>Breast Cancer Res.</i> (2016) 18:111. doi: 10.1186/s13058-016-0762-9</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27829436" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13058-016-0762-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=P.+Radice&#x00026;author=RL.+Milne&#x00026;author=FJ.+Couch&#x00026;author=MC.+Southey&#x00026;author=P.+Peterlongo+&#x00026;publication_year=2016&#x00026;title=The+PALB2+p&#x00026;journal=Breast+Cancer+Res.&#x00026;volume=18&#x00026;pages=111" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B24" id="B24"></a> 24. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. <i>EMBO Rep.</i> (2009) 10:990&#x02013;6. doi: 10.1038/embor.2009.126</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19609323" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/embor.2009.126" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AW.+Oliver&#x00026;author=S.+Swift&#x00026;author=CJ.+Lord&#x00026;author=A.+Ashworth&#x00026;author=LH.+Pearl+&#x00026;publication_year=2009&#x00026;title=Structural+basis+for+recruitment+of+BRCA2+by+PALB2&#x00026;journal=EMBO+Rep.&#x00026;volume=10&#x00026;pages=990-6" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B25" id="B25"></a> 25. Hussain H, Chong NF. Combined overlap extension PCR method for improved site directed mutagenesis. <i>Biomed Res Int.</i> (2016) 2016:8041532. doi: 10.1155/2016/8041532</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27995143" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1155/2016/8041532" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Hussain&#x00026;author=NF.+Chong+&#x00026;publication_year=2016&#x00026;title=Combined+overlap+extension+PCR+method+for+improved+site+directed+mutagenesis&#x00026;journal=Biomed+Res+Int.&#x00026;volume=2016&#x00026;pages=8041532" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B26" id="B26"></a> 26. Catucci I, Peterlongo P, Ciceri S, Colombo M, Pasquini G, Barile M, et al. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genet Med.</i> (2014) 16:688&#x02013;94. doi: 10.1038/gim.2014.13</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24556926" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/gim.2014.13" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=P.+Peterlongo&#x00026;author=S.+Ciceri&#x00026;author=M.+Colombo&#x00026;author=G.+Pasquini&#x00026;author=M.+Barile+&#x00026;publication_year=2014&#x00026;title=PALB2+sequencing+in+Italian+familial+breast+cancer+cases+reveals+a+high-risk+mutation+recurrent+in+the+province+of+Bergamo&#x00026;journal=Genet+Med.&#x00026;volume=16&#x00026;pages=688-94" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B27" id="B27"></a> 27. Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, et al. Haplotype analyses of the c.1027C&#x0003E;T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. <i>Breast Cancer Res Treat.</i> (2016) 160:121&#x02013;9. doi: 10.1007/s10549-016-3981-y</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27624329" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-016-3981-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=S.+Casadei&#x00026;author=YC.+Ding&#x00026;author=S.+Volorio&#x00026;author=F.+Ficarazzi&#x00026;author=A.+Falanga+&#x00026;publication_year=2016&#x00026;title=Haplotype+analyses+of+the+c&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=160&#x00026;pages=121-9" target="_blank">Google Scholar</a></p></div>
<div class="References" style="margin-bottom:0.5em; margin-left:2em;">
<p style="margin-left:0.7em; text-indent:-1.7em;" class="ReferencesCopy1"><a name="B28" id="B28"></a> 28. Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. <i>Oncogene</i> (2014) 33:4803&#x02013;12. doi: 10.1038/onc.2013.421</p>
<p style="margin-left:1em;" class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24141787" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/onc.2013.421" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JY.+Park&#x00026;author=TR.+Singh&#x00026;author=N.+Nassar&#x00026;author=F.+Zhang&#x00026;author=M.+Freund&#x00026;author=H.+Hanenberg+&#x00026;publication_year=2014&#x00026;title=Breast+cancer-associated+missense+mutants+of+the+PALB2+WD40+domain,+which+directly+binds+RAD51C,+RAD51+and+BRCA2,+disrupt+DNA+repair&#x00026;journal=Oncogene&#x00026;volume=33&#x00026;pages=4803-12" target="_blank">Google Scholar</a></p></div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords:</span> breast cancer, breast cancer predisposition genes, PALB2, BRCA2, VUS, functional analyses, PALB2-BRCA2 interacting domain</p>
<p><span>Citation:</span> Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P and Peterlongo P (2018) Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction. <i>Front. Oncol</i>. 8:480. doi: 10.3389/fonc.2018.00480</p>
<p id="timestamps"><span>Received:</span> 03 August 2018; <span>Accepted:</span> 08 October 2018;<br> <span>Published:</span> 25 October 2018.</p>
<div><p>Edited by:</p> <a href="http://loop.frontiersin.org/people/161686/overview">Haining Yang</a>, University of Hawaii Cancer Center, United States</div>
<div><p>Reviewed by:</p> <a href="http://loop.frontiersin.org/people/83328/overview">Adriana De Siervi</a>, Instituto de Biolog&#x000ED;a y Medicina Experimental (IBYME), Argentina<br> <a href="http://loop.frontiersin.org/people/206311/overview">Giovanni Gaudino</a>, Retired, Bellinzona, Switzerland</div>
<p><span>Copyright</span> &#x000A9; 2018 Caleca, Catucci, Figlioli, De Cecco, Pesaran, Ward, Volorio, Falanga, Marchetti, Iascone, Tondini, Zambelli, Azzollini, Manoukian, Radice and Peterlongo. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>*Correspondence:</span> Paolo Peterlongo, <a id="encmail">cGFvbG8ucGV0ZXJsb25nb0BpZm9tLmV1</a></p>
<div class="clear"></div></div>

</div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2018.00480" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">5,6K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,6K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">12</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/410473#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2018.00480" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2018.00480" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/161686/overview" data-event="editorInfo-a-hainingYang" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">H</span><span class="notranslate">Y</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Haining  Yang</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Hawaii Cancer Center, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/83328/overview" data-event="editorInfo-a-adrianaDeSiervi" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">A</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Adriana  De Siervi</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">CONICET Institute of Biology and Experimental Medicine (IBYME), Argentina</div></div></a><a href="https://loop.frontiersin.org/people/206311/overview" data-event="editorInfo-a-giovanniGaudino" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">G</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Giovanni  Gaudino</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">University of Hawaii Cancer Center, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Patients and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Author Contributions</a></li>
<li><a href="#h7">Funding</a></li>
<li><a href="#h8">Conflict of Interest Statement</a></li>
<li><a href="#h9">Acknowledgments</a></li>
<li><a href="#h10">Supplementary Material</a></li>
<li><a href="#h11">References</a></li>
</ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2018.00480" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2018.00480/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":937,"mainHeader":941},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":749,"currentArticlePageMetaInfo":750,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":543,"articleType":549,"stage":552,"keywords":554,"authors":562,"editors":678,"reviewers":687,"journal":704,"section":712,"impactMetrics":714,"volume":718,"articleVolume":719,"relatedArticles":720,"isPublishedV2":367,"contents":721,"files":724},410473,"10.3389/fonc.2018.00480","Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction",["Date","2018-10-08T12:46:29.000Z"],["Date","2018-08-03T14:04:18.000Z"],["Date","2018-10-25T00:00:00.000Z"],["Date","2025-11-25T05:04:02.528Z"],"PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA repair by homologous recombination. Germline pathogenic variants in BRCA1, BRCA2 and PALB2 DNA repair genes are associated with high risk of developing breast cancer. Mutation screening in these breast cancer predisposition genes is routinely performed and allows the identification of individuals who carry pathogenic variants and are at risk of developing the disease. However, variants of uncertain significance (VUSs) are often detected and establishing their pathogenicity and clinical relevance remains a central challenge for the risk assessment of the carriers and the clinical decision-making process. Many of these VUSs are missense variants leading to single amino acid substitutions, whose impact on protein function is uncertain. Typically, VUSs are rare and due to the limited genetic, clinical, and pathological data the multifactorial approaches used for classification cannot be applied. Thus, these variants can only be characterized through functional analyses comparing their effect with that of normal and mutant gene products used as positive and negative controls.\n\nPerforming mutation testing in breast cancer probands, we identify The two missense variants BRCA2:c.91T>G (p.Trp31Gly) and PALB2:c.3262C>T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. These variants were located in the BRCA2-PALB2 interacting domains, were predicted to be deleterious by in silico analyses, and were very rare and clinically not classified. Therefore, we initiate to study their functional effect by exploiting a green fluorescent protein (GFP)-reassembly in vitro assay specifically designed to test the BRCA2-PALB2 interaction. This functional assay proved to be easy to develop, robust and reliable. It also allows testing variants located in different genes. Results from these functional analyses showed that the BRCA2:p.Trp31Gly and the PALB2:p.Pro1088Ser prevented the BRCA2-PALB2 binding. While caution is warranted when the interpretation of the clinical significance of rare VUSs is based on functional studies only, our data provide initial evidences in favor of the possibility that these variants are pathogenic.\n",{"id":544,"title":545,"articlesCount":546,"isMagazinePage":13,"slug":547,"isOpenForSubmission":367,"views":548},7106,"Accomplishments, Collaborative Projects and Future Initiatives in Breast Cancer Genetic Predisposition",13,"accomplishments-collaborative-projects-and-future-initiatives-in-breast-cancer-genetic-predisposition",115658,{"id":550,"name":551},24,"Original Research",{"id":553,"name":19},18,[555,556,557,558,559,560,561],"breast cancer","breast cancer predisposition genes","PALB2","BRCA2","VUS","Functional analyses","BRCA2-PALB2 interacting domains",[563,572,580,586,593,602,610,619,627,633,640,647,653,660,666,673],{"id":564,"firstName":565,"middleName":19,"lastName":566,"givenNames":567,"isCorresponding":367,"isProfilePublic":13,"userId":564,"email":-1,"affiliations":568},612988,"Laura","Caleca","Laura ",[569],{"organizationName":570,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori","Italy",{"id":573,"firstName":574,"middleName":19,"lastName":575,"givenNames":576,"isCorresponding":367,"isProfilePublic":13,"userId":573,"email":-1,"affiliations":577},565028,"Irene","Catucci","Irene ",[578],{"organizationName":579,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology",{"id":388,"firstName":581,"middleName":19,"lastName":582,"givenNames":583,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":584},"Gisella","Figlioli","Gisella ",[585],{"organizationName":579,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":587,"middleName":19,"lastName":588,"givenNames":589,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":590},"Loris","De Cecco","Loris ",[591],{"organizationName":592,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori",{"id":594,"firstName":595,"middleName":19,"lastName":596,"givenNames":597,"isCorresponding":367,"isProfilePublic":13,"userId":594,"email":-1,"affiliations":598},581161,"Tina","Pesaran","Tina ",[599],{"organizationName":600,"countryName":601,"cityName":19,"stateName":19,"zipCode":19},"Ambry Genetics, Department of Clinical Diagnostics","United States",{"id":603,"firstName":604,"middleName":19,"lastName":605,"givenNames":606,"isCorresponding":367,"isProfilePublic":13,"userId":603,"email":-1,"affiliations":607},581114,"Maggie","Ward","Maggie ",[608],{"organizationName":609,"countryName":601,"cityName":19,"stateName":19,"zipCode":19},"Cancer Outreach and Risk Assessment, Via Christi Hospitals",{"id":388,"firstName":611,"middleName":19,"lastName":612,"givenNames":613,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":614},"Sara","Volorio","Sara ",[615,617],{"organizationName":616,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"IFOM, Fondazione Istituto FIRC di Oncologia Molecolare",{"organizationName":618,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Cogentech Cancer Genetics Test Laboratory",{"id":620,"firstName":621,"middleName":19,"lastName":622,"givenNames":623,"isCorresponding":367,"isProfilePublic":13,"userId":620,"email":-1,"affiliations":624},441249,"Anna","Falanga","Anna ",[625],{"organizationName":626,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII",{"id":388,"firstName":628,"middleName":19,"lastName":629,"givenNames":630,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":631},"Marina","Marchetti","Marina ",[632],{"organizationName":618,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":634,"middleName":19,"lastName":635,"givenNames":636,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":637},"Maria","Iascone","Maria ",[638],{"organizationName":639,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII",{"id":388,"firstName":641,"middleName":19,"lastName":642,"givenNames":643,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":644},"Carlo","Tondini","Carlo ",[645],{"organizationName":646,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII",{"id":388,"firstName":648,"middleName":19,"lastName":649,"givenNames":650,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":651},"Alberto","Zambelli","Alberto ",[652],{"organizationName":646,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":657},"Jacopo","Azzollini","Jacopo ",[658],{"organizationName":659,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},"Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori",{"id":388,"firstName":661,"middleName":19,"lastName":662,"givenNames":663,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":664},"Siranoush","Manoukian","Siranoush ",[665],{"organizationName":659,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},{"id":667,"firstName":668,"middleName":19,"lastName":669,"givenNames":670,"isCorresponding":367,"isProfilePublic":13,"userId":667,"email":-1,"affiliations":671},525518,"Paolo","Radice","Paolo ",[672],{"organizationName":570,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},{"id":674,"firstName":668,"middleName":19,"lastName":675,"givenNames":670,"isCorresponding":367,"isProfilePublic":13,"userId":674,"email":-1,"affiliations":676},489555,"Peterlongo",[677],{"organizationName":579,"countryName":571,"cityName":19,"stateName":19,"zipCode":19},[679],{"id":680,"firstName":681,"middleName":19,"lastName":682,"givenNames":683,"isCorresponding":367,"isProfilePublic":13,"userId":680,"email":-1,"affiliations":684},161686,"Haining","Yang","Haining ",[685],{"organizationName":686,"countryName":601,"cityName":19,"stateName":19,"zipCode":19},"University of Hawaii Cancer Center",[688,697],{"id":689,"firstName":690,"middleName":19,"lastName":691,"givenNames":692,"isCorresponding":367,"isProfilePublic":13,"userId":689,"email":-1,"affiliations":693},83328,"Adriana","De Siervi","Adriana ",[694],{"organizationName":695,"countryName":696,"cityName":19,"stateName":19,"zipCode":19},"CONICET Institute of Biology and Experimental Medicine (IBYME)","Argentina",{"id":698,"firstName":699,"middleName":19,"lastName":700,"givenNames":701,"isCorresponding":367,"isProfilePublic":13,"userId":698,"email":-1,"affiliations":702},206311,"Giovanni","Gaudino","Giovanni ",[703],{"organizationName":686,"countryName":601,"cityName":19,"stateName":19,"zipCode":19},{"id":115,"slug":117,"name":116,"shortName":705,"electronicISSN":706,"field":707,"specialtyId":28,"journalSectionPaths":710},"Front. Oncol.","2234-943X",{"id":708,"domainId":709},57,2,[711],{"section":712},{"id":184,"name":185,"slug":186,"specialtyId":713},1228,{"views":715,"downloads":716,"citations":717},5604,1648,12,8,"Volume 8 - 2018",[],{"titleHtml":537,"fullTextHtml":722,"menuHtml":723},"\u003Cdiv class=\"JournalAbstract\">\r\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\r\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\r\n\u003Ca href=\"https://loop.frontiersin.org/people/612988\" class=\"user-id-612988\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/612988/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\r\nLaura Caleca\">Laura Caleca\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/565028\" class=\"user-id-565028\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/565028/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Irene Catucci\">Irene Catucci\u003C/a>\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Gisella Figlioli\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Gisella Figlioli\u003Csup>2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Loris De Cecco\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Loris De Cecco\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/581161\" class=\"user-id-581161\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/581161/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Tina Pesaran\">Tina Pesaran\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/581114\" class=\"user-id-581114\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/581114/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Maggie Ward\">Maggie Ward\u003C/a>\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sara Volorio,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sara Volorio\u003Csup>6,7\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/441249\" class=\"user-id-441249\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/441249/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Anna Falanga\">Anna Falanga\u003C/a>\u003Csup>8\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Marina Marchetti\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Marina Marchetti\u003Csup>7\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Maria Iascone\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Maria Iascone\u003Csup>9\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Carlo Tondini\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Carlo Tondini\u003Csup>10\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Alberto Zambelli\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Alberto Zambelli\u003Csup>10\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jacopo Azzollini\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jacopo Azzollini\u003Csup>11\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Siranoush Manoukian\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Siranoush Manoukian\u003Csup>11\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/525518\" class=\"user-id-525518\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/525518/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Paolo Radice\">Paolo Radice\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/489555\" class=\"user-id-489555\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/489555/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Paolo Peterlongo*\">Paolo Peterlongo\u003C/a>\u003Csup>2\u003C/sup>\u003Csup>*\u003C/sup>\u003C/span>\u003C/div>\r\n\u003Cul class=\"notes\">\r\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Milan, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Ambry Genetics, Department of Clinical Diagnostics, Aliso Viejo, CA, United States\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Cancer Outreach and Risk Assessment, Via Christi Hospitals, Wichita, KS, United States\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>7\u003C/sup>\u003C/span>Cogentech Cancer Genetics Test Laboratory, Milan, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>8\u003C/sup>\u003C/span>Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>9\u003C/sup>\u003C/span>USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>10\u003C/sup>\u003C/span>Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>11\u003C/sup>\u003C/span>Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy\u003C/li>\r\n\u003C/ul>\r\n\u003Cp>PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA repair by homologous recombination. Germline pathogenic variants in \u003Ci>BRCA1, BRCA2\u003C/i> and \u003Ci>PALB2\u003C/i> DNA repair genes are associated with high risk of developing breast cancer. Mutation screening in these breast cancer predisposition genes is routinely performed and allows the identification of individuals who carry pathogenic variants and are at risk of developing the disease. However, variants of uncertain significance (VUSs) are often detected and establishing their pathogenicity and clinical relevance remains a central challenge for the risk assessment of the carriers and the clinical decision-making process. Many of these VUSs are missense variants leading to single amino acid substitutions, whose impact on protein function is uncertain. Typically, VUSs are rare and due to the limited genetic, clinical, and pathological data the multifactorial approaches used for classification cannot be applied. Thus, these variants can only be characterized through functional analyses comparing their effect with that of normal and mutant gene products used as positive and negative controls. The two missense variants \u003Ci>BRCA2\u003C/i>:c.91T &#x0003E;G (p.Trp31Gly) and \u003Ci>PALB2\u003C/i>:c.3262C &#x0003E;T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. These variants were located in the BRCA2-PALB2 interacting domains, were predicted to be deleterious by \u003Ci>in silico\u003C/i> analyses, and were very rare and clinically not classified. Therefore, we initiate to study their functional effect by exploiting a green fluorescent protein (GFP)-reassembly \u003Ci>in vitro\u003C/i> assay specifically designed to test the BRCA2-PALB2 interaction. This functional assay proved to be easy to develop, robust and reliable. It also allows testing variants located in different genes. Results from these functional analyses showed that the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser prevented the BRCA2-PALB2 binding. While caution is warranted when the interpretation of the clinical significance of rare VUSs is based on functional studies only, our data provide initial evidences in favor of the possibility that these variants are pathogenic.\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\r\n\u003Cdiv class=\"JournalFullText\">\r\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\r\n\u003Cp class=\"mb15\">Approximately 20% of the familial aggregation of breast cancer is related to the presence of germline pathogenic variants in the tumor suppressor high-risk genes \u003Ci>BRCA1\u003C/i> (MIM&#x00023;113705) and \u003Ci>BRCA2\u003C/i> (MIM&#x00023;600185) [reviewed in (\u003Ca href=\"#B1\">1\u003C/a>)]. Additional germline variants in several other genes, including \u003Ci>PALB2\u003C/i> (partner and localizer of BRCA2) (MIM&#x00023;610355) have also been implicated in increased predisposition to breast cancer (\u003Ca href=\"#B2\">2\u003C/a>, \u003Ca href=\"#B3\">3\u003C/a>). Estimated cumulative breast cancer risk by age of 70 conferred by pathogenic variants in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> is approximately 60 and 50%, respectively (\u003Ca href=\"#B4\">4\u003C/a>, \u003Ca href=\"#B5\">5\u003C/a>). Loss of function \u003Ci>PALB2\u003C/i> pathogenic variants confer a breast cancer risk of 35% by age of 70, that is comparable to that conferred by \u003Ci>BRCA2\u003C/i> pathogenic variants (\u003Ca href=\"#B6\">6\u003C/a>). Sequencing of these genes has become a key step of the clinical management of breast cancer families as the carriers of a pathogenic variants may be offered appropriate surveillance programs or risk reducing options, whereas the non-carriers may be advised to follow the same recommendations offered to the general population (\u003Ca href=\"#B7\">7\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The clinical utility and efficacy of genetic testing rely on the possibility to establish a correlation between the detected genetic variant and its protein functional effect. As an example, pathogenicity is generally inferred for variants introducing premature termination codons (PTCs), or affecting mRNA integrity and/or stability that give rise to functionally compromised proteins. However, the assessment of the clinical relevance of other variants, especially those that are rare, may not be equally straightforward. These are referred to as variants of uncertain significance (VUSs) and typically include missense variants, small in-frame deletions or insertions, exonic and intronic alterations potentially affecting the mRNA splicing, and variants in regulatory sequences (\u003Ca href=\"#B4\">4\u003C/a>, \u003Ca href=\"#B8\">8\u003C/a>). Many of such variants located in the \u003Ci>BRCA1, BRCA2\u003C/i>, and \u003Ci>PALB2\u003C/i> genes have been deposited as &#x0201C;unclassified&#x0201D; in publicly available databases. The current approach to clinically classify a VUS is the multifactorial likelihood prediction model in which, data from epidemiological, genetic, pathological and clinical analyses are combined in order to derive a posterior likelihood of pathogenicity. However, reaching odds ratios in favor of or against causality requires such analyses to be based on several independent observations or to be carried out in large sample series which are usually difficult to obtain if a variant is rare (\u003Ca href=\"#B9\">9\u003C/a>, \u003Ca href=\"#B10\">10\u003C/a>). This provides a compelling rationale to the inclusion in the multifactorial model of additional experimental evidences. As a possibility, VUSs &#x02014;especially those located in the coding regions&#x02014;can be studied using \u003Ci>in vitro\u003C/i> and functional assays that compare the effect of normal and mutant gene products.\u003C/p>\r\n\u003Cp class=\"mb15\">At the molecular level, PALB2 was identified as a binding partner of BRCA2 and was subsequently shown to bridge, via direct protein-protein interaction, BRCA1 and BRCA2 at sites of DNA damage (\u003Ca href=\"#B11\">11\u003C/a>&#x02013;\u003Ca href=\"#B13\">13\u003C/a>). Here, this complex promotes the repair by homologous recombination (HR) of the highly genotoxic DNA lesions, such as double-strand breaks (DSBs) or inter-strand crosslinks (ICLs) (\u003Ca href=\"#B14\">14\u003C/a>, \u003Ca href=\"#B15\">15\u003C/a>). These BRCA1-PALB2-BRCA2 interactions are mediated via the coiled-coil domains located at the N-terminus of PALB2 (amino acids 9-44) and at the C-terminus of BRCA1 (amino acids 1,393&#x02013;1,424), and by the seven-bladed &#x003B2;-propeller WD40 (tryptophan-aspartic acid rich) domain of the C-terminal end of PALB2 (amino acids 836&#x02013;1,186) binding a domain in the N-terminal end of the BRCA2 (amino acids 21&#x02013;39) (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B17\">17\u003C/a>). Functional assays based on these domain bindings were used to study patient-derived missense variants in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> to provide evidence in favor of or against pathogenicity. Three \u003Ci>BRCA2\u003C/i> missense variants, the c.73G&#x0003E;A (p.Gly25Arg), c.91T&#x0003E;C (p.Trp31Arg), and c.93G&#x0003E;T (p.Trp31Cys) were found to disrupt the BRCA2-PALB2 interaction, causing deficiencies in BRCA2 localization to the nucleus and in HR mediated DSB repair (\u003Ca href=\"#B16\">16\u003C/a>). Similarly, three \u003Ci>BRCA1\u003C/i> missense variants, the c.4198A&#x0003E;G (p.Met1400Val), c.4220T&#x0003E;C (p.Leu1407Pro), and c.4232T&#x0003E;C (p.Met1411Thr) abrogated or moderately impaired the BRCA1-PALB2 binding, causing reduced HR activity (\u003Ca href=\"#B17\">17\u003C/a>, \u003Ca href=\"#B18\">18\u003C/a>). To date, only few patient-derived missense variants in the \u003Ci>PALB2\u003C/i> gene have been investigated for pathogenicity. Among these, the \u003Ci>PALB2\u003C/i>:c.104T&#x0003E;C (p.Leu35Pro), located in the coiled-coil domain, was found to co-segregate with two breast cancer cases in a family with a strong history for the disease, and was shown to abrogate the BRCA1-PALB2 binding and to completely prevent HR and resistance to DNA damaging agents. As a result, the p.Leu35Pro was suggested to be a pathogenic variant (\u003Ca href=\"#B19\">19\u003C/a>) and is to our knowledge the sole variant in \u003Ci>PALB2\u003C/i> to date suggested to be pathogenic. All these findings emphasize that functional assays on VUS located in the BRCA1-PALB2-BRCA2 interaction domains may provide clues on their pathogenicity and that other variants affecting such interactions may be associated with breast cancer susceptibility.\u003C/p>\r\n\u003Cp class=\"mb0\">In the current study, we aimed to characterize functionally the two rare missense variants, \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) and \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G (p.Trp31Gly), that were initially identified in breast cancer families and that are located in the protein interaction domains. These two variants were tested for pathogenicity using the green fluorescent protein (GFP)-reassembly \u003Ci>in vitro\u003C/i> assay that was recently developed for the study of protein-protein interactions (\u003Ca href=\"#B20\">20\u003C/a>, \u003Ca href=\"#B21\">21\u003C/a>).\u003C/p>\r\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Patients and Methods\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Breast Cancer Probands and Genotyping Analysis\u003C/h3>\r\n\u003Cp class=\"mb15\">The two female Italian breast cancer probands included in this study were originally considered eligible for clinical genetic testing in breast cancer genes, based on criteria including age of onset for breast cancer and family history for the disease. One proband, recruited at the Genetics Unit of Fondazione IRCCS Istituto Nazionale dei Tumori in Milan (INT), was tested for mutations in the coding regions of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> by massively parallel sequencing, using TruSeq Custom Amplicon v.1.2 (Illumina), and multiplex ligation-dependent probe amplification (MLPA) resulting carrier of the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly. These tests were performed at Cogentech Cancer Genetic Test Laboratory (CGT Lab). The other proband, recruited at the Unit of Medical Oncology of the Ospedale Papa Giovanni XXIII in Bergamo (HPG23), was tested for mutations in the coding regions of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> by Sanger sequencing and MLPA at Cogentech CGT Lab. No \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> mutations were detected, and so this probands was tested at Laboratorio Genetica Medica, HPG23 by massively parallel sequencing using TruSight Cancer assay (Illumina). No pathogenic or likely pathogenic variants were found and the only deleterious variant detected was the missense \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variant.\u003C/p>\r\n\u003Cp class=\"mb15\">Genotyping of the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser was performed using a custom TaqMan assay (probes and experimental conditions are available upon request). This variant was tested in familial and consecutive breast cancer cases ascertained at HPG23, and in female blood donors used as controls recruited at the AVIS Bergamo.\u003C/p>\r\n\u003Cp class=\"mb0\">All individuals included in this study and herein described signed an informed consent to the use of their biological samples and clinical data for research project. This study was approved by Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and Ethical Committee of the Province of Bergamo.\u003C/p>\r\n\u003Ch3>Positive/Negative Controls for the GFP-Reassembly \u003Ci>in vitro\u003C/i> Assay\u003C/h3>\r\n\u003Cp class=\"mb0\">Six \u003Ci>BRCA2\u003C/i> or \u003Ci>PALB2\u003C/i> variants located in the protein interaction domain were included as positive and negative controls. The \u003Ci>PALB2\u003C/i>:c.2816T&#x0003E;G (p.Leu939Trp) variant was reported to be not associated with breast cancer risk and to not alter the protein DNA repair activity by HR (\u003Ca href=\"#B22\">22\u003C/a>, \u003Ca href=\"#B23\">23\u003C/a>). The \u003Ci>BRCA2\u003C/i>:c.79A&#x0003E;G (p.Ile27Val) and \u003Ci>PALB2\u003C/i>:c.3064AT&#x0003E;GC (p.Met1022Ala) missense variants were functionally tested and resulted not disrupting the BRCA2-PALB2 interaction (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B24\">24\u003C/a>). These three variants were used as positive controls. The three missense variants \u003Ci>BRCA2\u003C/i>:c.93G&#x0003E;T (p.Trp31Cys), \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;C (p.Trp31Arg) and \u003Ci>PALB2\u003C/i>:c. 3073G&#x0003E;A (p.Ala1025Arg) were reported to functionally prevent the BRCA2-PALB2 binding and were used as negative controls (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B24\">24\u003C/a>). All of these variants were patient-derived with the exception of the \u003Ci>PALB2\u003C/i>:p.Met1022Ala and \u003Ci>PALB2\u003C/i>:p.Ala1025Arg that were synthetically designed based on crystallography analyses.\u003C/p>\r\n\u003Ch3>Plasmid Construction\u003C/h3>\r\n\u003Cp class=\"mb0\">The pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP expression vectors, encoding anti-parallel leucine zipper motifs (Z) fused to the N-terminal or C-terminal fragment of the GFP Protein (NfrGFP and CfrGFP, respectively) (\u003Ca href=\"#B20\">20\u003C/a>) were kindly donated by TJ Magliery from the Ohio State University in Columbus (OH, USA). The DNA fragments encoding the N-terminal end of BRCA2 (amino acids 10&#x02013;40) and the WD40 domain of PALB2 (amino acids 836-1186) were amplified from the cDNA of the 293T cells by PCR. The purified PCR products were subcloned into pET11a-NfrGFP between \u003Ci>XhoI\u003C/i> and \u003Ci>BamHI\u003C/i> restriction sites and pMRBAD-Z-CfrGFP between \u003Ci>NcoI\u003C/i> and \u003Ci>AatII\u003C/i> restriction sites, replacing the fragments encoding Z motifs. The \u003Ci>BRCA2\u003C/i> c.79A&#x0003E;G (p.Ile27Val), c.91T&#x0003E;C (p.Trp31Arg), c.91T&#x0003E;G (p.Trp31Gly), c.93G&#x0003E;T (p.Trp31Cys) and the \u003Ci>PALB2\u003C/i> c.2816T&#x0003E;G (p.Leu939Trp), c.3073G&#x0003E;A (p.Ala1025Arg), c.3266C&#x0003E;T (p.Pro1088Ser) variants were obtained by direct mutagenesis of pET11a-NfrGFP-BRCA2 and of pMRBAD-PALB2-CfrGFP using the QuickChange XL Site-directed Mutagenesis Kit (Stratagene) according to the manufacturer&#x00027;s instruction. The \u003Ci>PALB2\u003C/i> c.3064AT&#x0003E;GC (p.Met1022Ala) was obtained by the overlap extension PCR mutagenesis method (\u003Ca href=\"#B25\">25\u003C/a>). The presence of variants in recombinant clones was verified by DNA sequencing (Eurofins Genomics).\u003C/p>\r\n\u003Ch3>GFP-Fragment Reassembly Screening\u003C/h3>\r\n\u003Cp class=\"mb0\">Compatible pairs of plasmids (pET11a-NfrGFP-BRCA2 and pMRBAD-PALB2-CfrGFP, both as wild-type and mutant forms) were co-transformed into BL21 (DE3) \u003Ci>E. coli\u003C/i> competent cells by electroporation. Single colonies were then picked and used to inoculate 2 ml of LB broth medium containing ampicillin (100 &#x003BC;g/ml) and kanamycin (35 &#x003BC;g/ml). Following overnight incubation at 37&#x000B0;C, the cultured cells were diluted 1:1,000 and 100 &#x003BC;l were plated on inducing LB agar (LBA) plates supplemented with 20 &#x003BC;M Isopropyl &#x003B2;-D-1-tiogalattopiranoside (IPTG) and 0.2% L-arabinose, to promote the expression of recombinant proteins. The plates were incubated at 30&#x000B0;C for 24 h and then 3 days at room temperature (RT). Fluorescence was observed after excitation with long-wave (365 nm) UV light in combination with the short pass (SP) emission filter using a Syngene image capture system (SYNGENE) as specified by the manufacturer.\u003C/p>\r\n\u003Ch3>Purification of the Reassembled GFP Complexes\u003C/h3>\r\n\u003Cp class=\"mb15\">The pET11a-NfrGFP-BRCA2 (both wt and mutant forms) also encode a hexa histidine (H\u003Csub>6\u003C/sub>)-tag at the N-terminus of the NfrGFP useful for rapid purification by Immobilized metal affinity chromatography (IMAC) method of the H\u003Csub>6\u003C/sub>-tagged proteins. This method exploits the strong binding of H\u003Csub>6\u003C/sub>-tagged protein to metal ions as nickel, allowing them to be separated from other proteins that have lower or no affinity.\u003C/p>\r\n\u003Cp class=\"mb0\">Co-transformed bacterial cells were recovered from inducing LBA media using a plate spreader and resuspended in two 1 ml-aliquots of 1X phosphate buffered saline (PBS). After centrifugation, each pellet was resuspended in 50 &#x003BC;l of 1xSDS loading buffer (whole cell extracts), or in 1 ml of lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 0.1% v/v Triton X-100, 100 &#x003BC;M EDTA pH8.0, 0.5 mg/ml lysozime, 20 mM Imidazole, protease inhibitors, 5 &#x003BC;g/ml DNase and RNase) for IMAC purification using the nickel nitrilotriacetic (Ni-NTA) agarose resin (QIAGEN), following the manufacturer&#x00027;s instructions. The purified protein complexes were subjected to 13% SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody (&#x00023;600-101-215; Rockland). Whole cell extracts were similarly resolved and visualized, to detect expression levels of the all NfrGFP-BRCA2 and CfrGFP-PALB2 fusion peptides.\u003C/p>\r\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Identification of the \u003Ci>BRCA2\u003C/i>:c.91t&#x0003E;G (p.Trp31Gly) and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) Variants\u003C/h3>\r\n\u003Cp class=\"mb0\">Part of our research activity stems from the collaboration with several Breast Cancer Units in which clinical genetic testing is routinely performed. One of our major interest is to functionally study and characterize VUSs in breast cancer genes. In this study, we report the identification and describe the initial functional analyses of the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variants. The \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variants were originally identified in two different Italian breast cancer probands born in Milano and Bergamo, respectively and are located in the BRCA2-PALB2 interacting domains. Both these probands developed breast cancer at a young age and reported a close relative affected with early onset breast cancer (&#x02264; 40 years). Unfortunately, we were not able to ascertain other family members to be genotyped in order to attempt co-segregation analyses (Figure \u003Ca href=\"#F1\">1\u003C/a>). None of these two variants were reported in public databases such as GnomAD and 1000 genomes. However, the \u003Ci>BRCA2\u003C/i>: &#x0003C; \u003Ci>underline\u003C/i> &#x0003E;p.Trp31Gly was annotated in ClinVar (\u003Ca href=\"https://www.ncbi.nlm.nih.gov/clinvar/\">https://www.ncbi.nlm.nih.gov/clinvar/\u003C/a>) in a single individual submitted by Ambry Genetics and classified as a VUS. On the contrary, the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser was not found in any of the clinical databases we searched. However, during the last annual meeting of the \u003Ci>PALB2\u003C/i> Interest Group (PIG; \u003Ca href=\"http://www.palb2.org/\">http://www.palb2.org/\u003C/a>) colleagues from Ambry Genetics reported the finding of an additional carrier of the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variant. To our knowledge, to date, this is only the second proband found to carry this variant. For this reason, we report here his clinical phenotype and family cancer history. This proband was a male affected with colorectal polyps, type unknown, and from a family with cases of melanoma and pancreatic cancer but not breast cancers (Figure \u003Ca href=\"#F2\">2\u003C/a>). Unfortunately, also in this case, no other samples were available for genotyping. We previously reported two different founder mutations, the \u003Ci>PALB2\u003C/i>:c.1027C&#x0003E;T (p.Gln343*) and the \u003Ci>BRCA2\u003C/i>:c.190T&#x0003E;C (p.Cys64Arg), originally identified in the Bergamo province where they have a carrier frequency approximately 10-fold higher than that of the Italian population (\u003Ca href=\"#B21\">21\u003C/a>, \u003Ca href=\"#B26\">26\u003C/a>, \u003Ca href=\"#B27\">27\u003C/a>). Hence, we genotyped the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser in 126 familial and 477 consecutive breast cancer cases, and 1,074 controls all born in the province of Bergamo but no additional carriers were found.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" name=\"figure1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 1\u003C/strong>. The \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G (p.Trp31Gly) and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) variants, and pedigrees of the two mutation carriers. \u003Cstrong>(A)\u003C/strong> Electropherograms showing the \u003Ci>BRCA2\u003C/i> and \u003Ci>PALB2\u003C/i> sequence of the individuals carrying the two variants, and normal controls. \u003Cstrong>(B)\u003C/strong> Family pedigrees 1 and 2 of the two Italians probands carrying the \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G (p.Trp31Gly;) and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) variants, respectively. Probands are indicated by arrow. Cancer type, age at diagnosis and age of death are reported when known. Age of healthy individuals, if known, was annotated at date of genetic counseling. Events occurred after genetic counseling, if known, are annotated. Additional relatives carrying the variants are indicated by &#43;/&#x02013;. Cancer type is reported as follows: Bl, bladder cancer; Br, breast cancer; CR, colorectal cancer; Le, leukemia; Lu, lung cancer.\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" name=\"figure2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 2\u003C/strong>. Family pedigree of the additional proband carrying the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) variant. The proband had large multi gene panel test (67 genes) due to a family history of cancer. The analysis was performed at the Ambry Genetics using Next Generation Sequencing and Array CGA (\u003Ca style=\"color:grey;\" href=\"https://www.ambrygen.com/clinician/genetic-testing/28/oncology/cancernext-expanded\">https://www.ambrygen.com/clinician/genetic-testing/28/oncology/cancernext-expanded\u003C/a>). Proband is indicated by arrow. Cancer type, age at diagnosis and age of death are reported when known. Age of healthy individuals, if known, was annotated at date of genetic counseling. Events occurred after genetic counseling, if known, are annotated. Cancer type is reported as follows: BC, basal cells cancer; Bl, bladder cancer; Me, melanoma; Pa, pancreatic cancer; Pr, prostate cancer; Un, unknown.\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch3>The \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G (p.Trp31Gly) and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) Variants Prevent the BRCA2-PALB2 Binding\u003C/h3>\r\n\u003Cp class=\"mb0\">The \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T variants were located within the protein domains mediating the BRCA2-PALB2 interaction (Figure \u003Ca href=\"#F3\">3A\u003C/a>). To evaluate the effect of these variants on the BRCA2-PALB2 interaction, we exploited a bimolecular fluorescence complementation-based assay, the GFP-reassembly \u003Ci>in vitro\u003C/i> assay. In this assay, the GFP is dissected into two fragments, the N-terminal, NfrGFP and the C-terminal, CfrGFP which are fused to the N-terminal end of BRCA2 (amino acids 10-40) and the WD40 domain of PALB2 (amino acids 836-1186), respectively. These two plasmids are co-expressed in BL21 (DE3) \u003Ci>E. coli\u003C/i> cells and only if BRCA2-PALB2 interaction occurs, the GFP reassemble emitting cellular fluorescence after ultraviolet (UV) irradiation.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" name=\"figure3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 3\u003C/strong>. Detection of the BRCA2-PALB2 interaction. \u003Cstrong>(A)\u003C/strong> Schematic representation of the specific domains mediating the BRCA2-PALB2 binding and of the location of variants analyzed in the present study. \u003Cstrong>(B)\u003C/strong> GFP-reassembly \u003Ci>in vitro\u003C/i> assay. Fluorescence was recovered, under long-wave UV light (365 nm), after 24 h of growth at 30&#x000B0;C followed by 3 days of incubation at room temperature. The variants PALB2 L939W or M1022A and BRCA2 I27V were included as positive controls. The variants PALB2 A1025R and BRCA2 W31C or W31R were included as negative controls. \u003Cstrong>(C)\u003C/strong> IMAC purification. The BRCA2-PALB2 reassembled complexes were purified from the co-transformed \u003Ci>E. coli\u003C/i> BL21 (DE3) cells, subjected to SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody. \u003Cstrong>(D)\u003C/strong> Analysis of expression of BRCA2-NfrGFP and PALB2-CfrGFP normal and mutant forms. Whole cell extracts from the co-transformed \u003Ci>E. coli\u003C/i> BL21 (DE3) cells were subjected to SDS-PAGE and visualized by Western blotting using a polyclonal anti-GFP antibody. Images of \u003Cstrong>(C, D)\u003C/strong> were selected from original autoradiographic films shown in Supplementary Figure \u003Ca style=\"color:grey;\" href=\"#SM1\">1\u003C/a>.\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Bright GFP fluorescence was observed in bacterial cells co-expressing NfrGFP fused with normal BRCA2 and CfrGFP fused with either normal PALB2, the clinically neutral variant \u003Ci>PALB2\u003C/i>:p.Leu939Trp or \u003Ci>PALB2\u003C/i>:p.Met1022Ala (positive controls). Similar results were observed in bacterial cells co-expressing CfrGFP fused with normal PALB2 and NfrGFP fused with \u003Ci>BRCA2\u003C/i>:p.Ile27Val (positive control). On the contrary, no fluorescence was observed in bacterial cells co-expressing NfrGFP fused with normal BRCA2 and CfrGFP fused with either \u003Ci>PALB2\u003C/i>:p.Pro1088Ser, or \u003Ci>PALB2\u003C/i>:p.Ala1025Arg (negative control). Similar results were observed in bacterial cells co-expressing CfrGFP fused with normal PALB2 and NfrGFP fused with either \u003Ci>BRCA2\u003C/i>:p.Trp31Gly, or the negative controls \u003Ci>BRCA2\u003C/i>:p.Trp31Cys, or \u003Ci>BRCA2\u003C/i>:p.Trp31Arg (Figure \u003Ca href=\"#F3\">3B\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">To confirm that GFP-reassembly was effectively due to the BRCA2-PALB2 interaction, the IMAC purified reassembled complexes were analyzed by Western blotting using a polyclonal anti-GFP antibody. Two bands corresponding to the components of the GFP reassembled complexes were detected in lysates of the bacterial cells that resulted fluorescent in the GFP-reassembly screening. On the contrary, no or low intensity bands corresponding to the PALB2-CfrGFP fused domains were observed in lysates from bacterial cells for whom no fluorescence was detected (Figure \u003Ca href=\"#F3\">3C\u003C/a>). In general, any mutations can cause the decrease or the complete loss of expression of the encoded GFP fused peptides. Thus, we wanted to confirm that the lack or the low intensity of the PALB2-CfrGFP bands was not due to loss of expression. To this aim, the whole cell extracts were analyzed by Western blotting using a polyclonal anti-GFP antibody as previously described. In this experiment, we showed that normal and mutated fusion peptides were expressed to a similar extent indicating that the loss of fluorescence observed in the GFP-reassembly \u003Ci>in vitro\u003C/i> assay, was attributable to the lack of binding between the proteins and not to poor expression of the mutants (Figure \u003Ca href=\"#F3\">3D\u003C/a>). All these results provided experimental evidence that both the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variants abrogate the BRCA2-PALB2 binding.\u003C/p>\r\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\r\n\u003Cp class=\"mb15\">In clinical settings, VUSs in breast cancer genes represent a serious issue in the process of disease risk assessment in carriers. Typically, results from different sources such as epidemiological, genetic, and clinical analyses are combined together in order to derive a posterior likelihood of pathogenicity used to classify a VUS. While this multifactorial approach is successful to classify common VUSs, variants that are rare or unique can only be studied through functional analyses.\u003C/p>\r\n\u003Cp class=\"mb15\">In the present study, we investigated the pathogenicity of the two \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and \u003Ci>PALB2\u003C/i>:p.Pro1088Ser variants performing functional analyses. The \u003Ci>BRCA2\u003C/i>:p.Trp31Gly was previously reported in a single proband and annotated as VUS. To our knowledge, the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser was never detected before. Both variants are located in the interaction domains of BRCA2 and PALB2. Large part of the BRCA2 functions in the repair of the DNA double strand breaks and inter-strand crosslinks by HR depends from its interaction with PALB2. Thus, we developed a GFP-reassembly assay based on the testing of this interaction speculating that this binding assay would be a predictor of the effect of the variants on the BRCA2 integrity.\u003C/p>\r\n\u003Cp class=\"mb15\">In the GFP-reassembly assay, we used six different \u003Ci>BRCA2\u003C/i> and \u003Ci>PALB2\u003C/i> missense variants as controls. Two patient-derived \u003Ci>BRCA2\u003C/i> variants, the p.Trp31Arg and p.Trp31Cys, and one synthetic \u003Ci>PALB2\u003C/i> variant, the p.Ala1025Arg, were known to prevent the BRCA2-PALB2 interaction. The patient derived \u003Ci>BRCA2\u003C/i>:p.Ile27Val and \u003Ci>PALB2\u003C/i>:Leu939Trp, and the synthetic \u003Ci>PALB2\u003C/i>:p.Met1022Ala were expected to not alter the binding of these proteins. For all of these variants, the results were concordant with their expected effect on the BRCA2-PALB2 binding.\u003C/p>\r\n\u003Cp class=\"mb15\">The GFP-reassembly assay results indicated that both the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and \u003Ci>PALB2\u003C/i>:p.Pro1088Ser prevented the BRCA2-PALB2 interaction suggesting that in physiological conditions these alleles encode proteins that might be unable to interact with PALB2 and BRCA2, respectively. To our knowledge, the \u003Ci>PALB2\u003C/i>:p.Pro1088Ser is the first missense variant in the gene that was functionally shown to abrogate the binding with BRCA2. As the correct formation of the BRCA1-PALB2-BRCA2 complex is necessary for DNA repair by HR, our results provide evidences in favor of the hypothesis that the \u003Ci>BRCA2\u003C/i>:p.Trp31Gly and \u003Ci>PALB2\u003C/i>:p.Pro1088Ser are pathogenic variants. While this assumption is at present most likely&#x02014;in example vs. the possibility that the variants are neutral&#x02014;other aspects need to be considered for a clearer picture of the effect of these variants on breast cancer risk. Firstly, Foo and colleagues showed that both the \u003Ci>PALB2\u003C/i>:p.Leu35Pro and p.Tyr28Cys caused the loss of the interaction with BRCA1; however, only the p.Leu35Pro completely abrogated the HR activity and the p.Tyr28Cys caused a loss of approximately 65% of the HR activity (\u003Ca href=\"#B19\">19\u003C/a>). Hence, \u003Ci>PALB2\u003C/i> missense variants causing the loss of the binding with BRCA1 might confer different risk magnitude for breast cancer. To be conservative, we cannot exclude that this might be true as well for the PALB2 variants abrogating the binding with BRCA2. As a second point, caution should be taken when inferring on the nature of a missense variant on the bases of functional studies only. Park and colleagues reported that the \u003Ci>PALB2\u003C/i>:p.Leu939Trp variant might be pathogenic based on the fact that it resulted in altered BRCA2-PALB2 binding, decreased HR capacity, and increased sensitivity to ionizing radiation (\u003Ca href=\"#B28\">28\u003C/a>). However, we provided strong evidences deriving from additional functional studies and very large case-control studies that the \u003Ci>PALB2\u003C/i>:p.Leu939Trp is a neutral variant (\u003Ca href=\"#B23\">23\u003C/a>). As a final consideration, it should be noted that of the many missense variants that were functionally proved to prevent the BRCA1-PALB2-BRCA2 complex formation (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B19\">19\u003C/a>, \u003Ca href=\"#B24\">24\u003C/a>), all, with the only exception of the \u003Ci>PALB2\u003C/i>:p.Leu939Trp that is consider benign or likely benign, are annotated or should be treated clinically as VUS.\u003C/p>\r\n\u003Cp class=\"mb0\">In conclusion, we report here results from functional studies indicating that the \u003Ci>BRCA2\u003C/i>:c.91T&#x0003E;G (p.Trp31Gly) and the \u003Ci>PALB2\u003C/i>:c.3262C&#x0003E;T (p.Pro1088Ser) missense variants abrogate the BRCA2-PALB2 protein binding. These data provide initial evidences corroborating the hypothesis that these variants are pathogenic. Importantly, novel data are warranted to progress in the clinical classification of these variants. The search for additional variant carriers and collection of their family members is crucial to provide genetic or pathological data; however, as the variants in study are very rare, we expect that not many variant carriers will be found in the near future. On the contrary, additional functional studies (i.e. testing specific protein functions in eukaryotic cells) could be immediately performed. While caution is warranted when clinical classification of a VUS is based on \u003Ci>in vitro\u003C/i> assays only, these results will provide additional evidences to better clarify the functional effect of the variants in study.\u003C/p>\r\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\r\n\u003Cp class=\"mb0\">PP and PR designed and supervised the study. TP, MW, SV, AF, MM, MI, CT, AZ, JA, and SM provided samples and data. LC, IC, and LD performed experiments. LC, IC, GF, PP, and PR analyzed data. LC, IC, PP, and PR wrote the manuscript. All authors contributing to, critically revised and approved the manuscript.\u003C/p>\r\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Funding\u003C/h2>\r\n\u003Cp class=\"mb0\">This work was partially supported by the following entities. Ministero della Salute, Italy Ricerca Finalizzata&#x02013;Bando 2010 to PP; AIRC (Associazione Italiana per la Ricerca sul Cancro) to PP (IG 16732), PR (IG 15547) and AF (5 &#x000D7; 1,000 n. 12237); Fondazione Umberto Veronesi (FUV-Post-doctoral Fellowships&#x02212;2016) to IC; the Italian citizens who allocated the 5 &#x000D7; 1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale dei Tumori, according to the Italian laws, to SM.\u003C/p>\r\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Conflict of Interest Statement\u003C/h2>\r\n\u003Cp class=\"mb15\">TP is a full time paid employee of Ambry Genetics.\u003C/p>\r\n\u003Cp class=\"mb0\">The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\r\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\r\n\u003Cp class=\"mb0\">We are particularly grateful to individuals participating in this study and their families. We also thank the Real Time PCR and the DNA Sequencing Service of Cogentech, Milan, Dr. Thomas J. Magliery from the Ohio State University in Columbus (OH, USA) for kindly providing the pET11a-NfrGFP-Z and pMRBAD-Z-CfrGFP plasmids necessary for the GFP-reassembly assay, Dr. Maria Teresa Radice of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, for technical assistance with plasmid construction and Drs. Cristina Zanzottera and Roberta Villa of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.\u003C/p>\r\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\r\n\u003Cp class=\"mb0\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2018.00480/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2018.00480/full#supplementary-material\u003C/a>\u003C/p>\r\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>References\u003C/h2>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. \u003Ci>Mol Oncol.\u003C/i> (2010) 4:174&#x02013;91. doi: 10.1016/j.molonc.2010.04.011\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20542480\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.molonc.2010.04.011\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N.+Mavaddat&#x00026;author=AC.+Antoniou&#x00026;author=DF.+Easton&#x00026;author=M.+Garcia-Closas+&#x00026;publication_year=2010&#x00026;title=Genetic+susceptibility+to+breast+cancer&#x00026;journal=Mol+Oncol.&#x00026;volume=4&#x00026;pages=174-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk. \u003Ci>N Engl J Med.\u003C/i> (2015) 372:2243&#x02013;57. doi: 10.1056/NEJMsr1501341\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26014596\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMsr1501341\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DF.+Easton&#x00026;author=PD.+Pharoah&#x00026;author=AC.+Antoniou&#x00026;author=M.+Tischkowitz&#x00026;author=SV.+Tavtigian&#x00026;author=KL.+Nathanson+&#x00026;publication_year=2015&#x00026;title=Gene-panel+sequencing+and+the+prediction+of+breast-cancer+risk&#x00026;journal=N+Engl+J+Med.&#x00026;volume=372&#x00026;pages=2243-57\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. \u003Ci>JAMA Oncol.\u003C/i> (2017) 3:1190&#x02013;6. doi: 10.1001/jamaoncol.2017.0424\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28418444\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jamaoncol.2017.0424\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FJ.+Couch&#x00026;author=H.+Shimelis&#x00026;author=C.+Hu&#x00026;author=SN.+Hart&#x00026;author=EC.+Polley&#x00026;author=J.+Na+&#x00026;publication_year=2017&#x00026;title=Associations+between+cancer+predisposition+testing+panel+genes+and+breast+cancer&#x00026;journal=JAMA+Oncol.&#x00026;volume=3&#x00026;pages=1190-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. \u003Ci>Science\u003C/i> (2014) 343:1466. doi: 10.1126/science.1251827\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24675953\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.1251827\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FJ Nathanson KL.+Couch&#x00026;author=K.+Offit+&#x00026;publication_year=2014&#x00026;title=Two+decades+after+BRCA%3A+setting+paradigms+in+personalized+cancer+care+and+prevention&#x00026;journal=Science&#x00026;volume=343&#x00026;pages=1466\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Foulkes WD. BRCA1 and BRCA2&#x02014;Update and implications on the genetics of breast cancer: a clinical perspective. \u003Ci>Clin Genet.\u003C/i> (2014) 85:1&#x02013;4. doi: 10.1111/cge.12291\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24116874\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12291\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=WD.+Foulkes+&#x00026;publication_year=2014&#x00026;title=BRCA1+and+BRCA2&#x02014;Update+and+implications+on+the+genetics+of+breast+cancer%3A+a+clinical+perspective&#x00026;journal=Clin+Genet.&#x00026;volume=85&#x00026;pages=1-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. \u003Ci>N Engl J Med.\u003C/i> (2014) 371:1651&#x02013;2. doi: 10.1056/NEJMc1410673\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1056/NEJMc1410673\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AC.+Antoniou&#x00026;author=WD.+Foulkes&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2014&#x00026;title=Breast-cancer+risk+in+families+with+mutations+in+PALB2&#x00026;journal=N+Engl+J+Med.&#x00026;volume=371&#x00026;pages=1651-2\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Girardi F, Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, et al. Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. \u003Ci>Genet Med.\u003C/i> (2018). doi: 10.1038/gim.2018.44\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"https://doi.org/10.1038/gim.2018.44\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Girardi&#x00026;author=DR.+Barnes&#x00026;author=D.+Barrowdale&#x00026;author=D.+Frost&#x00026;author=AF.+Brady&#x00026;author=C.+Miller+&#x00026;publication_year=2018&#x00026;title=Risks+of+breast+or+ovarian+cancer+in+BRCA1+or+BRCA2+predictive+test+negatives%3A+findings+from+the+EMBRACE+study&#x00026;journal=Genet+Med.\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. \u003Ci>Ann Oncol.\u003C/i> (2011) 22(Suppl 1):i18&#x02013;23. doi: 10.1093/annonc/mdq661\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21285146\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdq661\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=P.+Radice&#x00026;author=Summa S.+De&#x00026;author=L.+Caleca&#x00026;author=S.+Tommasi+&#x00026;publication_year=2011&#x00026;title=Unclassified+variants+in+BRCA+genes%3A+guidelines+for+interpretation&#x00026;journal=Ann+Oncol.&#x00026;volume=22&#x00026;pages=i18-23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.1em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. \u003Ci>Curr Opin Genet Dev.\u003C/i> (2010) 20:315&#x02013;23. doi: 10.1016/j.gde.2010.03.009\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20456937\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.gde.2010.03.009\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AB.+Spurdle+&#x00026;publication_year=2010&#x00026;title=Clinical+relevance+of+rare+germline+sequence+variants+in+cancer+genes%3A+evolution+and+application+of+classification+models&#x00026;journal=Curr+Opin+Genet+Dev.&#x00026;volume=20&#x00026;pages=315-23\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Lindor NM, Guidugli L, Wang X, Vall&#x000E9;e MP, Monteiro AN, Tavtigian S, et al. A review of a multifactorial probability based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). \u003Ci>Hum Mutat.\u003C/i> (2012) 33:8&#x02013;21. doi: 10.1002/humu.21627\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21990134\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.21627\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=NM.+Lindor&#x00026;author=L.+Guidugli&#x00026;author=X.+Wang&#x00026;author=MP.+Vall&#x000E9;e&#x00026;author=AN.+Monteiro&#x00026;author=S.+Tavtigian+&#x00026;publication_year=2012&#x00026;title=A+review+of+a+multifactorial+probability+based+model+for+classification+of+BRCA1+and+BRCA2+variants+of+uncertain+significance+(VUS)&#x00026;journal=Hum+Mutat.&#x00026;volume=33&#x00026;pages=8-21\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY. Exploring the roles of PALB2 at the crossroads of DNA repair and cancer. \u003Ci>Biochem J.\u003C/i> (2014) 460:331&#x02013;42. doi: 10.1042/BJ20140208\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24870022\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1042/BJ20140208\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+Pauty&#x00026;author=A.+Rodrigue&#x00026;author=A.+Couturier&#x00026;author=R.+Buisson&#x00026;author=JY.+Masson+&#x00026;publication_year=2014&#x00026;title=Exploring+the+roles+of+PALB2+at+the+crossroads+of+DNA+repair+and+cancer&#x00026;journal=Biochem+J.&#x00026;volume=460&#x00026;pages=331-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. \u003Ci>Mol Cancer Res.\u003C/i> (2009) 7:1110&#x02013;8. doi: 10.1158/1541-7786.MCR-09-0123\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19584259\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1541-7786.MCR-09-0123\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Zhang&#x00026;author=Q.+Fan&#x00026;author=K.+Ren&#x00026;author=PR.+Andreassen+&#x00026;publication_year=2009&#x00026;title=PALB2+functionally+connects+the+breast+cancer+susceptibility+proteins+BRCA1+and+BRCA2&#x00026;journal=Mol+Cancer+Res.&#x00026;volume=7&#x00026;pages=1110-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. \u003Ci>Curr Biol.\u003C/i> (2009) 19:524&#x02013;9. doi: 10.1016/j.cub.2009.02.018\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19268590\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cub.2009.02.018\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Zhang&#x00026;author=J.+Ma&#x00026;author=J.+Wu&#x00026;author=L.+Ye&#x00026;author=H.+Cai&#x00026;author=B.+Xia+&#x00026;publication_year=2009&#x00026;title=PALB2+links+BRCA1+and+BRCA2+in+the+DNA-damage+response&#x00026;journal=Curr+Biol.&#x00026;volume=19&#x00026;pages=524-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Ceccaldi R, Sarangi P, D&#x00027;Andrea AD. The Fanconi anaemia pathway: new players and new functions. \u003Ci>Nat Rev Mol Cell Biol.\u003C/i> (2016) 17:337&#x02013;49. doi: 10.1038/nrm.2016.48\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27145721\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrm.2016.48\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Ceccaldi&#x00026;author=P.+Sarangi&#x00026;author=AD.+D&#x00027;Andrea+&#x00026;publication_year=2016&#x00026;title=The+Fanconi+anaemia+pathway%3A+new+players+and+new+functions&#x00026;journal=Nat+Rev+Mol+Cell+Biol.&#x00026;volume=17&#x00026;pages=337-49\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. \u003Ci>Cold Spring Harb Perspect Biol.\u003C/i> (2015) 7:a016600. doi: 10.1101/cshperspect.a016600\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25833843\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/cshperspect.a016600\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Prakash&#x00026;author=Y.+Zhang&#x00026;author=W.+Feng&#x00026;author=M.+Jasin+&#x00026;publication_year=2015&#x00026;title=Homologous+recombination+and+human+health%3A+the+roles+of+BRCA1,+BRCA2,+and+associated+proteins&#x00026;journal=Cold+Spring+Harb+Perspect+Biol.&#x00026;volume=7&#x00026;pages=a016600\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. \u003Ci>Mol Cell\u003C/i> (2006) 22:719&#x02013;29. doi: 10.1016/j.molcel.2006.05.022\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16793542\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.molcel.2006.05.022\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B.+Xia&#x00026;author=Q.+Sheng&#x00026;author=K.+Nakanishi&#x00026;author=A.+Ohashi&#x00026;author=J.+Wu&#x00026;author=N.+Christ+&#x00026;publication_year=2006&#x00026;title=Control+of+BRCA2+cellular+and+clinical+functions+by+a+nuclear+partner,+PALB2&#x00026;journal=Mol+Cell&#x00026;volume=22&#x00026;pages=719-29\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. \u003Ci>Proc Natl Acad Sci USA.\u003C/i> (2009) 106:7155&#x02013;60. doi: 10.1073/pnas.0811159106\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19369211\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1073/pnas.0811159106\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SM.+Sy&#x00026;author=MS.+Huen&#x00026;author=J.+Chen+&#x00026;publication_year=2009&#x00026;title=PALB2+is+an+integral+component+of+the+BRCA+complex+required+for+homologous+recombination+repair&#x00026;journal=Proc+Natl+Acad+Sci+USA.&#x00026;volume=106&#x00026;pages=7155-60\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, et al. Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. \u003Ci>Elife\u003C/i> (2017) 6:e21350. doi: 10.7554/eLife.21350\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28398198\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.7554/eLife.21350\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RW.+Anantha&#x00026;author=S.+Simhadri&#x00026;author=TK.+Foo&#x00026;author=S.+Miao&#x00026;author=J.+Liu&#x00026;author=Z.+Shen+&#x00026;publication_year=2017&#x00026;title=Functional+and+mutational+landscapes+of+BRCA1+for+homology-directed+repair+and+therapy+resistance&#x00026;journal=Elife&#x00026;volume=6&#x00026;pages=e21350\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, et al. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk. \u003Ci>Oncogene\u003C/i> (2017) 36:4161&#x02013;70. doi: 10.1038/onc.2017.46\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28319063\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/onc.2017.46\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TK.+Foo&#x00026;author=M.+Tischkowitz&#x00026;author=S.+Simhadri&#x00026;author=T.+Boshari&#x00026;author=N.+Zayed&#x00026;author=KA.+Burke+&#x00026;publication_year=2017&#x00026;title=Compromised+BRCA1-PALB2+interaction+is+associated+with+breast+cancer+risk&#x00026;journal=Oncogene&#x00026;volume=36&#x00026;pages=4161-70\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Sarkar M, Magliery TJ. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients. \u003Ci>Mol Biosyst.\u003C/i> (2008) 4:599&#x02013;605. doi: 10.1039/b802481b\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18493658\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1039/b802481b\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Sarkar&#x00026;author=TJ.+Magliery+&#x00026;publication_year=2008&#x00026;title=Re-engineering+a+split-GFP+reassembly+screen+to+examine+RING-domain+interactions+between+BARD1+and+BRCA1+mutants+observed+in+cancer+patients&#x00026;journal=Mol+Biosyst.&#x00026;volume=4&#x00026;pages=599-605\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, et al. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. \u003Ci>PLoS ONE\u003C/i> (2014) 9:e86924. doi: 10.1371/journal.pone.0086924\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24516540\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0086924\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Caleca&#x00026;author=AL.+Putignano&#x00026;author=M.+Colombo&#x00026;author=C.+Congregati&#x00026;author=M.+Sarkar&#x00026;author=TJ.+Magliery+&#x00026;publication_year=2014&#x00026;title=Characterization+of+an+Italian+founder+mutation+in+the+RING-finger+domain+of+BRCA1&#x00026;journal=PLoS+ONE&#x00026;volume=9&#x00026;pages=e86924\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Southey MC, Winship I, Nguyen-Dumont T. PALB2: research reaching to clinical outcomes for women with breast cancer. \u003Ci>Hered Cancer Clin Pract.\u003C/i> (2016) 14:9. doi: 10.1186/s13053-016-0049-2\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27099641\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13053-016-0049-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MC.+Southey&#x00026;author=I.+Winship&#x00026;author=T.+Nguyen-Dumont+&#x00026;publication_year=2016&#x00026;title=PALB2%3A+research+reaching+to+clinical+outcomes+for+women+with+breast+cancer&#x00026;journal=Hered+Cancer+Clin+Pract.&#x00026;volume=14&#x00026;pages=9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Catucci I, Radice P, Milne RL, Couch FJ, Southey MC, Peterlongo P. The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk. \u003Ci>Breast Cancer Res.\u003C/i> (2016) 18:111. doi: 10.1186/s13058-016-0762-9\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27829436\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13058-016-0762-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=P.+Radice&#x00026;author=RL.+Milne&#x00026;author=FJ.+Couch&#x00026;author=MC.+Southey&#x00026;author=P.+Peterlongo+&#x00026;publication_year=2016&#x00026;title=The+PALB2+p&#x00026;journal=Breast+Cancer+Res.&#x00026;volume=18&#x00026;pages=111\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. \u003Ci>EMBO Rep.\u003C/i> (2009) 10:990&#x02013;6. doi: 10.1038/embor.2009.126\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19609323\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/embor.2009.126\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=AW.+Oliver&#x00026;author=S.+Swift&#x00026;author=CJ.+Lord&#x00026;author=A.+Ashworth&#x00026;author=LH.+Pearl+&#x00026;publication_year=2009&#x00026;title=Structural+basis+for+recruitment+of+BRCA2+by+PALB2&#x00026;journal=EMBO+Rep.&#x00026;volume=10&#x00026;pages=990-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Hussain H, Chong NF. Combined overlap extension PCR method for improved site directed mutagenesis. \u003Ci>Biomed Res Int.\u003C/i> (2016) 2016:8041532. doi: 10.1155/2016/8041532\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27995143\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1155/2016/8041532\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Hussain&#x00026;author=NF.+Chong+&#x00026;publication_year=2016&#x00026;title=Combined+overlap+extension+PCR+method+for+improved+site+directed+mutagenesis&#x00026;journal=Biomed+Res+Int.&#x00026;volume=2016&#x00026;pages=8041532\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Catucci I, Peterlongo P, Ciceri S, Colombo M, Pasquini G, Barile M, et al. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. \u003Ci>Genet Med.\u003C/i> (2014) 16:688&#x02013;94. doi: 10.1038/gim.2014.13\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24556926\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/gim.2014.13\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=P.+Peterlongo&#x00026;author=S.+Ciceri&#x00026;author=M.+Colombo&#x00026;author=G.+Pasquini&#x00026;author=M.+Barile+&#x00026;publication_year=2014&#x00026;title=PALB2+sequencing+in+Italian+familial+breast+cancer+cases+reveals+a+high-risk+mutation+recurrent+in+the+province+of+Bergamo&#x00026;journal=Genet+Med.&#x00026;volume=16&#x00026;pages=688-94\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Catucci I, Casadei S, Ding YC, Volorio S, Ficarazzi F, Falanga A, et al. Haplotype analyses of the c.1027C&#x0003E;T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. \u003Ci>Breast Cancer Res Treat.\u003C/i> (2016) 160:121&#x02013;9. doi: 10.1007/s10549-016-3981-y\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27624329\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-016-3981-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I.+Catucci&#x00026;author=S.+Casadei&#x00026;author=YC.+Ding&#x00026;author=S.+Volorio&#x00026;author=F.+Ficarazzi&#x00026;author=A.+Falanga+&#x00026;publication_year=2016&#x00026;title=Haplotype+analyses+of+the+c&#x00026;journal=Breast+Cancer+Res+Treat.&#x00026;volume=160&#x00026;pages=121-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\r\n\u003Cp style=\"margin-left:0.7em; text-indent:-1.7em;\" class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. \u003Ci>Oncogene\u003C/i> (2014) 33:4803&#x02013;12. doi: 10.1038/onc.2013.421\u003C/p>\r\n\u003Cp style=\"margin-left:1em;\" class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24141787\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/onc.2013.421\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JY.+Park&#x00026;author=TR.+Singh&#x00026;author=N.+Nassar&#x00026;author=F.+Zhang&#x00026;author=M.+Freund&#x00026;author=H.+Hanenberg+&#x00026;publication_year=2014&#x00026;title=Breast+cancer-associated+missense+mutants+of+the+PALB2+WD40+domain,+which+directly+binds+RAD51C,+RAD51+and+BRCA2,+disrupt+DNA+repair&#x00026;journal=Oncogene&#x00026;volume=33&#x00026;pages=4803-12\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\r\n\u003Cdiv class=\"AbstractSummary\">\r\n\u003Cp>\u003Cspan>Keywords:\u003C/span> breast cancer, breast cancer predisposition genes, PALB2, BRCA2, VUS, functional analyses, PALB2-BRCA2 interacting domain\u003C/p>\r\n\u003Cp>\u003Cspan>Citation:\u003C/span> Caleca L, Catucci I, Figlioli G, De Cecco L, Pesaran T, Ward M, Volorio S, Falanga A, Marchetti M, Iascone M, Tondini C, Zambelli A, Azzollini J, Manoukian S, Radice P and Peterlongo P (2018) Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction. \u003Ci>Front. Oncol\u003C/i>. 8:480. doi: 10.3389/fonc.2018.00480\u003C/p>\r\n\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 03 August 2018; \u003Cspan>Accepted:\u003C/span> 08 October 2018;\u003Cbr> \u003Cspan>Published:\u003C/span> 25 October 2018.\u003C/p>\r\n\u003Cdiv>\u003Cp>Edited by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/161686/overview\">Haining Yang\u003C/a>, University of Hawaii Cancer Center, United States\u003C/div>\r\n\u003Cdiv>\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/83328/overview\">Adriana De Siervi\u003C/a>, Instituto de Biolog&#x000ED;a y Medicina Experimental (IBYME), Argentina\u003Cbr> \u003Ca href=\"http://loop.frontiersin.org/people/206311/overview\">Giovanni Gaudino\u003C/a>, Retired, Bellinzona, Switzerland\u003C/div>\r\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2018 Caleca, Catucci, Figlioli, De Cecco, Pesaran, Ward, Volorio, Falanga, Marchetti, Iascone, Tondini, Zambelli, Azzollini, Manoukian, Radice and Peterlongo. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\r\n\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Paolo Peterlongo, \u003Ca id=\"encmail\">cGFvbG8ucGV0ZXJsb25nb0BpZm9tLmV1\u003C/a>\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\r\n\r\n","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Patients and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Conflict of Interest Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Acknowledgments\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">References\u003C/a>\u003C/li>\r\n\u003C/ul>",[725,730,736,739,745],{"name":726,"fileServerPackageEntryId":19,"fileServerId":727,"fileServerVersionNumber":709,"type":728},"EPUB.epub","410473/epub",{"code":729,"name":729},"EPUB",{"name":731,"fileServerPackageEntryId":732,"fileServerId":733,"fileServerVersionNumber":709,"type":734},"fonc-08-00480.pdf","fonc-08-00480-r1/fonc-08-00480.pdf","410473/pubmed-zip",{"code":735,"name":735},"PDF",{"name":731,"fileServerPackageEntryId":19,"fileServerId":737,"fileServerVersionNumber":709,"type":738},"410473/publishers-proof/pdf",{"code":735,"name":735},{"name":740,"fileServerPackageEntryId":741,"fileServerId":733,"fileServerVersionNumber":709,"type":742},"fonc-08-00480.xml","fonc-08-00480-r1/fonc-08-00480.xml",{"code":743,"name":744},"NLM_XML","XML",{"name":746,"fileServerPackageEntryId":19,"fileServerId":747,"fileServerVersionNumber":391,"type":748},"Provisional PDF.pdf","410473/provisional-pdf",{"code":735,"name":735},"v3",{"title":751,"link":752,"meta":756,"script":925},"Frontiers | Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction",[753],{"rel":754,"href":755},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/full",[757,760,763,765,768,772,775,779,782,785,788,790,792,794,796,798,801,804,806,809,812,814,817,820,823,826,829,833,837,840,843,846,848,851,854,857,860,863,866,869,872,875,878,881,884,887,890,893,896,899,901,904,907,910,912,915,917,920,922],{"hid":758,"property":758,"name":758,"content":759},"description","PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA r...",{"hid":761,"property":761,"name":762,"content":751},"og:title","title",{"hid":764,"property":764,"name":758,"content":759},"og:description",{"hid":766,"name":766,"content":767},"keywords","breast cancer,breast cancer predisposition genes,PALB2,BRCA2,VUS,Functional analyses,BRCA2-PALB2 interacting domains",{"hid":769,"property":769,"name":770,"content":771},"og:site_name","site_name","Frontiers",{"hid":773,"property":773,"name":384,"content":774},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/410473/fonc-08-00480-HTML-r1/image_m/fonc-08-00480-g001.jpg",{"hid":776,"property":776,"name":777,"content":778},"og:type","type","article",{"hid":780,"property":780,"name":781,"content":755},"og:url","url",{"hid":783,"name":783,"content":784},"twitter:card","summary_large_image",{"hid":786,"name":786,"content":787},"citation_volume","8",{"hid":789,"name":789,"content":116},"citation_journal_title",{"hid":791,"name":791,"content":771},"citation_publisher",{"hid":793,"name":793,"content":705},"citation_journal_abbrev",{"hid":795,"name":795,"content":706},"citation_issn",{"hid":797,"name":797,"content":536},"citation_doi",{"hid":799,"name":799,"content":800},"citation_firstpage","410473",{"hid":802,"name":802,"content":803},"citation_language","English",{"hid":805,"name":805,"content":537},"citation_title",{"hid":807,"name":807,"content":808},"citation_keywords","breast cancer; breast cancer predisposition genes; PALB2; BRCA2; VUS; Functional analyses; BRCA2-PALB2 interacting domains",{"hid":810,"name":810,"content":811},"citation_abstract","PALB2 (partner and localizer of BRCA2) was initially identified as a binding partner of BRCA2. It interacts also with BRCA1 forming a complex promoting DNA repair by homologous recombination. Germline pathogenic variants in BRCA1, BRCA2 and PALB2 DNA repair genes are associated with high risk of developing breast cancer. Mutation screening in these breast cancer predisposition genes is routinely performed and allows the identification of individuals who carry pathogenic variants and are at risk of developing the disease. However, variants of uncertain significance (VUSs) are often detected and establishing their pathogenicity and clinical relevance remains a central challenge for the risk assessment of the carriers and the clinical decision-making process. Many of these VUSs are missense variants leading to single amino acid substitutions, whose impact on protein function is uncertain. Typically, VUSs are rare and due to the limited genetic, clinical, and pathological data the multifactorial approaches used for classification cannot be applied. Thus, these variants can only be characterized through functional analyses comparing their effect with that of normal and mutant gene products used as positive and negative controls.Performing mutation testing in breast cancer probands, we identify The two missense variants BRCA2:c.91T>G (p.Trp31Gly) and PALB2:c.3262C>T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. These variants were located in the BRCA2-PALB2 interacting domains, were predicted to be deleterious by in silico analyses, and were very rare and clinically not classified. Therefore, we initiate to study their functional effect by exploiting a green fluorescent protein (GFP)-reassembly in vitro assay specifically designed to test the BRCA2-PALB2 interaction. This functional assay proved to be easy to develop, robust and reliable. It also allows testing variants located in different genes. Results from these functional analyses showed that the BRCA2:p.Trp31Gly and the PALB2:p.Pro1088Ser prevented the BRCA2-PALB2 binding. While caution is warranted when the interpretation of the clinical significance of rare VUSs is based on functional studies only, our data provide initial evidences in favor of the possibility that these variants are pathogenic.",{"hid":813,"name":813,"content":551},"citation_article_type",{"hid":815,"name":815,"content":816},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/pdf",{"hid":818,"name":818,"content":819},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00480/xml",{"hid":821,"name":821,"content":822},"citation_fulltext_world_readable","yes",{"hid":824,"name":824,"content":825},"citation_online_date","2018/10/08",{"hid":827,"name":827,"content":828},"citation_publication_date","2018/10/25",{"hid":830,"name":831,"content":832},"citation_author_0","citation_author","Caleca, Laura ",{"hid":834,"name":835,"content":836},"citation_author_institution_0","citation_author_institution","Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy",{"hid":838,"name":831,"content":839},"citation_author_1","Catucci, Irene ",{"hid":841,"name":835,"content":842},"citation_author_institution_1","Genome Diagnostics Program, IFOM the FIRC Institute of Molecular Oncology, Italy",{"hid":844,"name":831,"content":845},"citation_author_2","Figlioli, Gisella ",{"hid":847,"name":835,"content":842},"citation_author_institution_2",{"hid":849,"name":831,"content":850},"citation_author_3","De Cecco, Loris ",{"hid":852,"name":835,"content":853},"citation_author_institution_3","Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy",{"hid":855,"name":831,"content":856},"citation_author_4","Pesaran, Tina ",{"hid":858,"name":835,"content":859},"citation_author_institution_4","Ambry Genetics, Department of Clinical Diagnostics, United States",{"hid":861,"name":831,"content":862},"citation_author_5","Ward, Maggie ",{"hid":864,"name":835,"content":865},"citation_author_institution_5","Cancer Outreach and Risk Assessment, Via Christi Hospitals, United States",{"hid":867,"name":831,"content":868},"citation_author_6","Volorio, Sara ",{"hid":870,"name":835,"content":871},"citation_author_institution_6","IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Italy",{"hid":873,"name":831,"content":874},"citation_author_7","Falanga, Anna ",{"hid":876,"name":835,"content":877},"citation_author_institution_7","Department of Immunohematology and Transfusion Medicine, Azienda Ospedaliera Papa Giovanni XXIII, Italy",{"hid":879,"name":831,"content":880},"citation_author_8","Marchetti, Marina ",{"hid":882,"name":835,"content":883},"citation_author_institution_8","Cogentech Cancer Genetics Test Laboratory, Italy",{"hid":885,"name":831,"content":886},"citation_author_9","Iascone, Maria ",{"hid":888,"name":835,"content":889},"citation_author_institution_9","USSD Laboratorio Genetica Medica, Azienda Ospedaliera Papa Giovanni XXIII, Italy",{"hid":891,"name":831,"content":892},"citation_author_10","Tondini, Carlo ",{"hid":894,"name":835,"content":895},"citation_author_institution_10","Unit of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Italy",{"hid":897,"name":831,"content":898},"citation_author_11","Zambelli, Alberto ",{"hid":900,"name":835,"content":895},"citation_author_institution_11",{"hid":902,"name":831,"content":903},"citation_author_12","Azzollini, Jacopo ",{"hid":905,"name":835,"content":906},"citation_author_institution_12","Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy",{"hid":908,"name":831,"content":909},"citation_author_13","Manoukian, Siranoush ",{"hid":911,"name":835,"content":906},"citation_author_institution_13",{"hid":913,"name":831,"content":914},"citation_author_14","Radice, Paolo ",{"hid":916,"name":835,"content":836},"citation_author_institution_14",{"hid":918,"name":831,"content":919},"citation_author_15","Peterlongo, Paolo ",{"hid":921,"name":835,"content":842},"citation_author_institution_15",{"hid":923,"name":923,"content":924},"dc.identifier","doi:10.3389/fonc.2018.00480",[926,929,931,933,935],{"src":927,"body":13,"type":928,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":930,"body":13,"type":928,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":932,"body":13,"type":928,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":934,"body":13,"type":928,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2018.00480?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":936,"body":13,"type":928,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":938,"articleHubArticlesList":939,"canJournalHasArticleHub":367,"articleDoiList":940},{},[],[],{"title":19,"image":-1,"breadcrumbs":942,"linksCollection":943,"metricsCollection":945},[],{"total":388,"items":944},[],{"total":388,"items":946},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2018.00480?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>